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+ End tracking proteins +TIP
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5
Microtubule-associated protein MAP
Mitogen-activated protein kinase 2            ERK2
Multidrug resistance protein 1     MRP1
Multiple sclerosis                                        MS
Multiple system atrophy                  MSA
Myelin basic protein MBP
N-acetyltransferase                NAT1    
Nuclear magnetic resonance spectroscopy                 NMR
Parkinson’s disease                       PD
Permeability from apical-to-basolateral     Pab 
Permeability from basolateral-to-apical        Pba
P-glycoprotein    P-gp, MDR1
Phosphate buffered saline                 PBS
Poly-L-ornitine PLO
Polymerase chain reaction                                       PCR
Polyvinylidene fluoride                         PVDF
Post-translational modification PTM
Reverse phase-high performance liquid chromatography RP-HPLC
Ribonucleic acid  RNA 
Ribonucleic acid interference                     RNAi
Silent information regulator 2                        SIRT2
Small interfering RNA                 siRNA
Sodium dodecyl-sulfate polyacrylamide gel electrophoresis                    SDS-PAGE
Surface plasmon resonance SPR








Microtubules are major structural components in cells. They are important in the 
development and maintenance of cell shape, cell division and cellular movement (Wilson 1995).
The dynamics and organization of microtubules are central to their biological functions: they 
allow microtubules to rapidly reorganize, to differentiate spatially and temporally in accordance 
with the cell context (Conde 2009) and to generate such various patterns as interphase and spindle 
microtubules (Kinoshita 2002).
Microtubule dynamics and organization are regulated by a wide arsenal of regulatory 
proteins, including microtubule assembly-promoting factors, microtubule stabilizing factors (such as
structural microtubule-associated proteins (MAPs)), microtubule destabilizing factors, microtubule 
severing proteins and microtubule-based motors of the kinesin and dynein superfamilies (Conde 
2009). 
Tubulin polymerization promoting protein (TPPP/p25) was identified in our research group 
as a new MAP that promotes the polymerization of tubulin into microtubules and induces their 
bundling in vitro (Hlavanda 2002). In HeLa cells, expressing TPPP/p25 ectopically, the protein 
speci cally and dynamically co-localizes with the microtubule network and promotes the formation 
of microtubule bundles (Lehotzky 2004). In vivo, the protein was found to be expressed in the 
oligodendrocytes of normal human brain (Takahashi 1991, 1993), however, its intracellular function 
was not evaluated. Abnormal accumulation of TPPP/p25 is associated with neuronal and glial 
cytoplasmic inclusions in neuropathological conditions such as Parkinson’s disease (PD), multiple
system atrophy (MSA) and other synucleinopathies (Kovács 2004), and the protein was also 
identified as a marker for oligodendroglial changes in multiple sclerosis (MS) (Vincze 2010, 
Hoftberger 2010).
Besides the numerous regulatory proteins, microtubule dynamics and organization can be 
influenced by the chemically diverse groups of anticancer drugs used in chemotherapy, such as the 
different derivatives of vinblastine and paclitaxel (Orosz 2006). These effective antimitotic agents, 
in spite of their undesired toxic side effects and low bioavailability due to the process known as 
multidrug resistance (MDR), are effectively used in chemotherapy. However, it is great challenge 
for the drug researchers to produce new derivatives with much lower side effects and better 
bioavailability.
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KAR-2 and 17-desacetylvinblastineTrp-Arg8 are the representatives of new vinblastine 
derivatives that were syntethized by our co-workers Drs Keve and Ács from Richter-Gedeon Plc. 
and by Prof. Hudecz from Eötvös Loránd University, respectively, in order to generate new 
antimitotic agents with reduced side effects and higher bioavailability than that of the drug 
molecules used in cancer therapy nowadays. The major structural difference between KAR-2 and its
mother molecule is the formation of a spiro-ring at the vindoline part of the bisindole (Orosz 1999), 
while 17-desacetylvinblastineTrp-Arg8 contains an octaarginine, cell-penetrating peptide sequence 
conjugated through a Trp moiety to 17-desacetylvinblastine (Bánóczi 2010). The higher in vivo
efficiency of KAR-2 in animal tests (Orosz 1997) and the increased efficacy of 17-
desacetylvinblastineTrp-Arg8 on drug resistant human leukaemia (HL-60) cells as compared to 
vinblastine (Bánóczi 2010) indicated that they are promising anticancer agents.
The major objective of my Ph. D. thesis was the investigation of the dynamics and 
organization of the microtubule network in relation to its association with TPPP/p25 and the two 
new, potential anticancer agents in order to i): identify TPPP/p25-derived intracellular events that 
could indicate the role of TPPP/p25 in oligodendrocytes ii) evaluate the anti-microtubule and 
antimitotic activities of the new drug candidates that may contribute to the development of new 




3. 1 The cytoskeleton of eukaryotic cells
Most animal cells have three types of cytoskeletal filaments. Microtubules determine the 
positions of the membrane-enclosed organelles and direct intracellular transport, while during cell 
division they rearrange themselves to form bipolar mitotic spindles and play role in the chromosome 
segregation. They can also form motile whips, called cilia and flagella, or tightly aligned bundles 
that serve as tracks for the transport processes down along the long projections of some specialized 
cell types. Actin filaments underlie the plasma membrane of animal cells providing strength and 
shape to its thin lipid bilayer and are necessary for whole cell locomotion. They also form many 
types of cell surface projections, like lamellipodia and filopodia that cells use to explore territory. 
Finally, an actin-based contractile ring assembles transiently during mitosis to help the segregation 
of the two daughter cells. The third type of cytoskeletal filaments, the intermediate filaments, 
provides mechanical strength. Among them some line at the inner face of the nuclear envelope, 
forming a protective cage for the cell’s DNA, while others in the cytosol are twisted into strong 
cables that can hold epithelial cell sheets together or help nerve cells to extend long and robust 
axons (Alberts 2008).
3.1.1 The organization of microtubules
Microtubules are hollow rods approximately 24 nm in diameter composed of a single type of 
globular protein, called tubulin (Cooper 2000). The tubulin subunit is itself a heterodimer formed 
from two closely related globular proteins called -tubulin and -tubulin, tightly bound together by 
non-covalent bonds. Each or monomer has a binding site for one molecule of GTP. The GTP 
that is bound to the -tubulin monomer is physically trapped at the dimer interface and is never to 
be hydrolyzed or exchanged. The nucleotide on the -tubulin, in contrast, may be in either the GTP-
or the GDP-bound form, and it is exchangeable (Alberts 2008). Tubulin dimers polymerize to form 
microtubules, which generally consist of 13 linear protofilaments - composed of head-to-tail arrays 
of tubulin dimers - assembled around a hollow core (Cooper 2000). 
Microtubule growth/shrinkage is the consequence of the association/dissociation of a tubulin 
subunit to either ends of the filament (Alberts 2008). The speed of association/dissociation is 
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entirely dependent on the cytosolic concentration of available tubulin heterodimers in the 
surrounding volume. Critical concentration is that free heterodimer concentration where the rates of 
association and dissociation are equal (Kovács 1999). This critical concentration is not identical at 
the two ends. In a structurally polar filament, the kinetic rate constants for association and 
dissociation (kon and koff, respectively) are often much greater at one end than the other. The more 
dynamic of the two ends of a filament, where both growth and shrinkage are fast, is called the plus 
end, and the other end is called the minus end (Alberts 2008).   
Microtubule polymerization is significantly influenced by the GTPase activity of the -tubulin.
The GTP bound to -tubulin is hydrolyzed to GDP during or shortly after polymerization. This GTP 
hydrolysis weakens the binding affinity of tubulin for adjacent molecules, thereby favouring
depolymerization. In microtubules, GTP hydrolysis results in the behaviour known as dynamic 
instability, in which individual microtubules alternate between cycles of growth and shrinkage;
however, the total amount of microtubules remains almost constant within a certain time interval. 
Whether a microtubule grows or shrinks is determined by the rate of tubulin association relative to 
the rate of GTP hydrolysis. As long as new GTP-bound tubulin molecules are added more rapidly 
than GTP is hydrolyzed, the microtubule retains a GTP cap at its plus end and microtubule growth 
continues. However, if the rate of polymerization slows, the GTP bound to tubulin at the plus end of 
the microtubule will be hydrolyzed to GDP. If this occurs, the GDP-bound tubulin will dissociate, 
resulting in rapid depolymerization and shrinkage of the microtubule (Cooper 2000). Thus, 
individual microtubules do not reach a steady-state length, but exists in either polymerization 
(growth) or depolymerization (shrinkage) state (Alberts 2008), however, in vivo a microtubule end 
may also ‘‘pause’’ in an intermediate state between growing and shrinking for some time (Figure 1)
(Conde 2009) .
Figure 1: Organization of microtubules.
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3.1.2 Dynamic instability of microtubules
The dynamic instability of microtubules is characterized by four main parameters: the rates of 
microtubule growth and shrinking, the frequency of transition from growth or pause to shortening 
(called catastrophe) and the frequency of transition from shortening to growth or pause (called 
rescue). The parameter called “dynamicity” is used to describe the overall rate of exchange of 
tubulin subunits at microtubule ends (Jordan 2002). This unique behaviour suggested interesting
models for how microtubule turnover could be used to generate such asymmetric patterns of 
microtubules as interphase microtubules and mitotic spindles (Kinohita 2002).      
In a typical cell in interphase, the microtubules radiate from a central site near the nucleus, 
called the microtubule-organizing centre. In animal cells, there is a single, well-defined
microtubule-organizing centre called centrosome. This centrosome is composed of a pair of 
centrioles surrounded by the pericentriolar material containing an isoform of tubulin ( -tubulin) in a 
large complex that includes other proteins and functions as nucleating seed: the -tubulin ring 
complex (Alberts 2008, Heald 2002). The minus ends of the microtubules lie in the centrosome and 
the plus ends extend out toward the cell periphery. Prior to mitosis the centrosome duplicates, then 
the two centrosomes separate and become the poles of the forming mitotic spindle. Afterwards, the 
microtubules of the interphase array depolymerize and, as the nuclear envelope breaks down and 
releases the now condensed chromosomes, a spindle-shaped array of newly assembled microtubules 
is organized (Jordan 2002).
Dynamic instability of microtubules changes through the cell cycle (Kinoshita 2002). The 
interphase microtubule network disassembles at the onset of mitosis and is replaced by a new 
population of spindle microtubules that is more dynamic than the microtubules in the interphase 
cytoskeleton. In interphase cells, microtubules exchange their tubulin with soluble tubulin from the 
cytoplasmic pool relatively slowly, with half-times that range from several minutes to several hours. 
Mitotic spindle microtubules exchange their tubulin with tubulin of the soluble pool with half-times 
in the order of 10 - 30 seconds (Jordan 2002).
The dynamics of spindle microtubules is central to their biological functions. During 
prometaphase, microtubules emanating from each of the two spindle poles make vast growing and 
shrinking excursions, essentially probing the cytoplasm until they "find" and become attached to a 
chromosome at the kinetochore. Such microtubules must be able to grow for long distances 
(typically 5-10 m), then shorten almost completely, and then re-grow again until they successfully 
become attached to the kinetochores. During metaphase the duplicated chromosomes, which are 
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attached to the microtubules at their kinetochores, oscillate back and forth under considerable 
tension in the spindle equatorial region in concert with growth and shortening of the attached 
microtubules. These oscillations are required for proper construction of the spindle and for the cell-
cycle signalling at the metaphase/anaphase checkpoint. Either the absence of tension on the 
chromosomal kinetochores or the presence of a single chromosome that is unable to achieve a 
bipolar attachment to the spindle is sufficient to block the cell cycle progress from metaphase to 
anaphase; the cell then remains blocked in a prometaphase/metaphase-like state and eventually 
undergoes apoptotic or programmed cell death (Jordan 2002).
In interphase the polymerization dynamics of microtubules allows microtubules to rapidly 
reorganize, to differentiate spatially and temporally in accordance with the cell context, to generate 
pushing and pulling forces and it is involved in the mechanism of cell polarization (Conde 2009).
3.1.2.1 Cellular factors influencing microtubule dynamics and organization
Besides the critical concentration and the GTPase activity of the -tubulin, microtubule 
dynamics and organization are further modified in the cell by interactions with cellular factors that 
stabilize or destabilize microtubules. These factors operate in spatially and temporally speci c ways 
to generate different microtubule assemblies during the cell cycle (Heald 2002).
Tubulin monomer folding by the chaperonin-containing TCP-1 (CCT) and the formation of 
functional dimers by folding cofactors determine, together with transcriptional control, the amount 
of subunits available to polymerize (Heald 2002).
Microtubule dynamics and organization are also influenced by microtubule-associated 
proteins (MAPs). Among them structural MAPs bind to, stabilize and promote the assembly of 
microtubules. Their well known representatives are MAPla and lb, MAP2a 2b, and 2c, MAP4, tau 
protein, 205 kDa MAP, and isoforms of these proteins that are often generated by alternative 
splicing (Mandelkow 1995). These structural MAPs organize the individual filaments, attach to 
each other in larger-scale structures in order to form a useful intracellular scaffold. The mechanism 
that cells use to organize filaments into large structures is called bundling (Alberts 2008). 
Considering its function: it was proved in case of several neuronal MAPs that bundled microtubules 
display increased stability against microtubule depolymerization (Takemura 1992, Umeyama 1993,
Barlow 1994) providing long-lived and well-organized tracks for the polarized intracellular 
trafficking events (Richter-Landsberg 2000, 2008).
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Other MAPs have dramatic effects on the dynamic instability of microtubules. They can 
influence the rate at which a microtubule switches from a growing to a shrinking state (the 
frequency of catastrophes) or from a shrinking to a growing state (the frequency of rescues). For 
example, a family of kinesin-related proteins (depolymerizing kinesins of the KinI family), known 
as catastrophe factors, significantly increases the catastrophe rate. They bind specifically to 
microtubule ends and seem to pry protofilaments apart, lowering the normal activation energy 
barrier that prevents a microtubule from springing (Alberts 2008, Heald 2002). The ubiquitous 
XMAP215 has a special ability to stabilize free microtubule ends and to inhibit their switch from a 
growing to a shrinking state (Alberts 2008). The microtubule destabilizing factor katanin functions 
as a severing factor, generating new ends lacking a GTP cap. Op18/Stathmin has been proposed to 
act by sequestering tubulin dimers and/or by promoting GTP hydrolysis (Heald 2002).
The plus-end tracking proteins (+ TIPs), like the End Binding proteins (EBs) or cytoplasmic 
linker proteins (CLIPs), may copolymerize with new tubulin subunits and appear to rocket around 
the cell at the ends of the rapidly growing microtubules (Alberts 2008). A subset of these +TIPs also 
modulates the growth and shrinkage of the microtubule end to which they are attached, while others 
control microtubule positioning helping to capture and stabilize the growing microtubule end 
(Alberts 2008). EB1, that dynamically tracks growing microtubule plus ends via multiple rounds of 
association at the newly growing end and rapid dissociation from the older part of the lattice, for 
example, stabilizes microtubules in vivo and stimulates spontaneous microtubule nucleation and 
growth in vitro (Wade 2009). 
Nevertheless, microtubule-stabilizing and -destabilizing factors function by a variety of 
mechanisms and may themselves be regulated both temporally by activation of kinases and 
phosphatases and spatially through specific localization of factors (Heald 2002).
3.1.2.1.1 The TPPP/p25
Tubulin polymerization promoting protein (TPPP/p25) is an intrinsically unstructured 
protein that, in vitro, promotes the polymerization of tubulin into normal microtubules or into
polymorphic tubulin aggregates and induces microtubule bundling depending on its phosphorylation 
state (Figure 2) (Hlavanda 2002, 2007). 
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Figure 2: Electron microscopic images of the TPPP/p25-induced tubulin assemblies before (A, B) 
and after phosphorylation (C) with ERK2. A and B: Bundles of microtubules sectioned at different angles 
and thread-like oligomers aggregated into dense knobs are shown. The microtubules are frequently covered 
by tiny projections and periodically arranged dense particles (B) which form cross-links between 
microtubules (see insert in panel B). C: Sample prepared with phosphorylated TPPP/p25 contains loosely 
arranged oligomeric threads. Bars: 200 nm in (A) and (C); 100 nm in (B) and 50 nm in the insert in (B).
In HeLa cells, expressing TPPP/p25 ectopically, the protein is speci cally co-localizes with 
the microtubule network (Figure 3). This co-localization is dynamic as demonstrated by 
Fluorescence recovery after photobleaching (FRAP) experiments. At low expression level, the 
presence of the protein has no influence on the architecture of the microtubule network, cell 
morphology and viability, the progress of the cell cycle and the energetic state of the cells (Lehotzky 
2004). However, high level of EGFP-TPPP/p25 promotes cell death and reorganizes the 
microtubule network into two characteristic aberrant ultrastructures. On one hand, a perinuclear 
cage is formed from the TPPP/p25-bundled microtubules (Figure 3C cell marked 3); on the other 
hand, an aggresome, a characteristic protein aggregation in the centrosome region (Kopito 2000)
(Figure 3C cell marked 2) is formed in response to misfolded protein stress (Lehotzky 2004, 
Kawaguchi 2003). This aggresome mimics the formation of pathological brain inclusions (Kopito 
2000). 
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Figure 3: Microtubule network of HeLa cells transfected with pEGFP-TPPP/p25. Representative 
images of transiently transfected HeLa cells immunostained for -tubulin show three TPPP/p25-transfected 
cells with distinct morphologies depending on the TPPP/p25 expression level. Note the co-localization 
(orange) of EGFP-TPPP/p25 (green) with the microtubule network (red) at low expression level (cell 
marked 1), within the perinuclear cage (cell marked 3) and within the aggresome forming cell (cell marked 
2). Scale bar: 10 m.
In vivo, TPPP/p25 was originally identi ed within the oligodendrocytes and neuropil in rat 
brain (Takahashi 1993, Skjoerringe 2006), in oligodendrocytes within white matter tracts and in 
perineuronal oligodendrocyte cells of the human cortex (Kovács 2007). Moreover, in silico 
comparative genomic studies as well as proteomic experiments showed that TPPP genes are 
conserved in the genomes of ciliated organisms but are lacking from non-ciliated ones. As ciliary 
structures are microtubule-based cellular extensions of sensory and/or motile function, intimate 
relationship between TPPP/p25 expression and cilia formation was propounded (Orosz 2008). 
Finally, TPPP/p25 was also associated with different neurodegenerative diseases. The protein is 
enriched in the -synuclein bearing Lewy bodies of PD and diffuse Lewy body disease (Figure 4A-
C), as well as in the glial cytoplasmic inclusions of MSA (Figure 4D-F) and was also identified as a 
marker for oligodendroglial changes in MS (Kovács 2004, Vincze 2010, Hoftberger 2010), while 
the lack of TPPP/p25 expression was revealed in oligodendrogliomas (Preusser 2007).
Figure 4: Co-localization of TPPP/p25 and -synuclein in pathological brain inclusions. TPPP/p25 
(p25, green) and synuclein ( -syn, red) show co-localization in Lewy bodies of Parkinson’s disease (A-C, 
×500) and in glial cytoplasmic inclusions of multiple system atrophy (D-F, ×500).
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3.1.2.2 Drugs influencing microtubule dynamics and organization
Microtubule targeting molecules occur as self-protecting, toxic molecules in plants (Orosz 
2006). They usually target the tubulin/microtubule network of cytoskeleton destroying its dynamic 
character and organization (Orosz 1999).
One group of these drugs, including the Vinca alkaloids, cryptophycins, halichondrins, 
estramustine and colchicine, inhibits microtubule polymerization at high drug concentrations. 
Another rapidly expanding group of these drugs stimulates microtubule polymerization and 
stabilizes microtubules at high concentrations. These include paclitaxel, eleutherobins, epothilones, 
laulimalide and discodermolide (Jordan 2002). 
At relatively low concentrations, both groups of drugs block mitosis and inhibit cell 
proliferation by a common action. They suppress the dynamics of microtubules at the plus ends 
whereas they enhance dynamic instability at the minus ends without appreciably changing the total 
amount of microtubules in the cell. The dynamics of spindle microtubules is significantly faster than 
that of interphase microtubules, therefore, the disruption of microtubule dynamics makes mitosis so 
exquisitely sensitive to paclitaxel, vinblastine, and other antimitotic drugs (Jordan 2002).
Vinca-alkaloids, such as vincristine and vinblastine (VBL), were the earliest isolated form 
Catharanthus roseus. Structurally they are bisindole alkaloids consisting of a catharanthine and a 
vindoline moiety. Vindoline constitutes the most complex half of vinblastine, and it is both a 
biosynthetic and synthetic precursor of the natural product (Orosz 2006).
The chemical conversion of bisindoles into semi-synthetic agents is motivated by the 
extensive need for potent anticancer drugs in clinical chemotherapy (Orosz 1999). These semi-
synthetic molecules are modified in either the catharanthine or in the vindoline moieties, bearing 
several reactive centres. At the beginning, vinblastine was used as starting molecule since it was the 
only product readily available in relatively large quantity in the plant extract. Modification of the 
methyl ester group at position C-16 of the vindoline part resulted in the synthesis of the first semi-
synthetic clinically active Vinca alkaloid, vindesine (desacetylvinblastine amide sulfate) (Orosz
2006). 
Despite the efficacy of these molecules their use in clinical chemotherapy is still limited. 
Cancer chemotherapy requires the preferential killing of rapidly proliferating cancer cells. The lack 
of specificity leads to systemic toxicity causing undesirable side effects (Orosz 2006), while the 
mechanism known as MDR reduces their bioavailability (Juliano 1976, Debenham 1982, Cole 
1992).
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To eliminate or reduce the side effects, semi-synthetic compounds were prepared by 
different modifications of vinbastine. Such attempt, for example, was the modifications of the 
amide group by incorporating different alkyl groups or amino acids. Among the amino acid 
derivatives, the hydrophobic amino acid (Leu, Ile, Val and Trp) containing derivatives showed 
pronounced activity. The Trp-OEt derivative had an outstanding effect on P388 and L1210 
leukaemias implanted intravenously in DBA2 mice (Bánóczi 2010).
To increase the efficiency of a drug against resistant cells is a difficult task to achieve. Many 
drugs have to be administered using the parenteral route due to their low intestinal permeabilities 
and intestinal secretion processes mediated by transporters such as P-glycoprotein (P-gp).
Vinblastine is a substrate of P-gp, and thus it displays a low intestinal permeability (Gonzales-
Alvarez 2008). The conjugation of small drug molecules to carriers could be a potential strategy for 
utilization, as the conjugate could exhibit increased efficiency against resistant cells, for example,
due to the altered internalization pathway. Oligoarginines, as cell-penetrating peptides, can transport 
covalently attached compounds into different kinds of cells and enhance their efficiency. Different 
oligoarginines were used efficiently to transport genetically or chemically attached proteins, 
peptides and noncovalently bound plasmid DNAs or small molecules into cells. Among them 
oligoarginines: hexa-, hepta- and octaarginine showed the most effective internalization (Bánóczi 
2010).
3.1.2.2.1 KAR-2
The  KAR  compounds,  synthesized  by  chemists  of  Richter  Gedeon Plc.,  were  screened  
in  our  laboratory  for  their  anticancer activities  in various  systems,  and  KAR-2 was selected 
for further analysis (Orosz 1999). KAR-2 is a derivative of 4-deacetoxy-vinblastine isolated from 
Catharanthus roseus. The major structural difference between KAR-2 and the mother molecule is a 
spiro-ring at the vindoline part of the bisindole formed by the addition of chloroethyl-isocyanate in 
tetrahydrofurane (Figure 5) (Orosz 2006).
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Figure 5: Scheme of KAR-2 synthesis. Compound I: 4-deacetoxy-vinblastine, compound II: 
KAR-2, R1= CH3, R2= CH2CH2Cl
In spite of the structural differences, the two drugs bind to the vinca site of tubulin with
comparable affinity, however, the cytotoxicity of KAR-2 is significantly lower. In vivo, KAR-2 was
found to be a powerful antitumour agent on mouse leukaemia P388, however, its administration did 
not induce neurotoxic side effects, as observed in the case of bisindoles routinely used in therapy.
Moreover, KAR-2 was found to be effective even in a single high dose, whereas vincristine used in 
the same administration schedule was toxic or less effective (Table 1) (Orosz 1997).
Our research group demonstrated that the binding affinities of the vinblastine and KAR-2 to 
calmodulin are similar, however, KAR-2 does not exhibit anti-calmodulin activity (Orosz 1997).
These data suggest that higher cytotoxicity of vinblastine, as compared to that of KAR-2, may be 
originated from its additional influence on calmodulin-mediated processes indispensible for various
cell functions (Orosz 1997).
In vivo effect Cytotoxicity 
P388 (MTA)
Drug (single doses)
Maximal effect         Dose IC50 ( M)
    T/C (%)                mg/kg-1
KAR-2     207± 27                  60 0.31 ± 0.006
vinblastine 0.005 ± 0.001
vincristine     147± 36                    1 0.013 ±  0.001
Table 1: Effect of KAR-2 in various tests. In vivo antitumour effects in mouse P388 leukaemias 
and microculture tetrazolium assay (MTA) assay on SH-SY5Y human neuroblastoma cells.
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Cellular transport studies and in situ intestinal perfusion experiments in rats, carried out by 
our co-worker Prof. M. Bermejo from Universidad Miguel Hernández, showed that vinblastine and 
KAR-2 are substrates of secretion transporters but with different affinity. KAR-2 perform much 
better penetration potency into cancer cells because its affinity to P-gp is almost negligible, 
moreover it presents higher passive diffusion permeability (Figure 6). Thus, KAR-2 displays much 
better absorption profile and penetration characteristics than its mother molecule, and permeabilities 
at 10–100 mM concentration range could be enough to ensure appropriate oral absorption 
(Gonzales-Alvarez 2008).
Figure 6: Permeabilities of vinblastine and KAR-2 obtained in different cell lines, at different 
concentrations of the compounds. Drug permeabilities from apical-to-basolateral (Pab) and from basolateral-
to-apical (Pba) sides in polarized MDCK, MDCK cells overexpressing MDR1 protein, and Caco-2 cells.
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3.1.2.2.2 Vinblastine derivative-octaarginine conjugates
17-desacetylvinblastineTrp derivatives with different length of polyarginine tail (tetra-, hexa-
and octaarginine) were synthetized by Prof. Hudecz from Eötvös Loránd University in order to 
enhance the efficiency against resistant cells and reduce undesired side effects of its mother 
molecule. In the first step of their synthesis, vinblastine was coupled to the N-terminal amino 
function of L-Trp methyl ester through its carboxyl group at position 16. After hydrolysis of the 
ester group, 17-desacetylvinblastineTrp was conjugated to the N-terminal amino group of 
oligoarginine via the C-terminal carboxyl group of the Trp moiety in solution (Figure 7) (Bánóczi 
2010). 
Figure 7: Structure proposed for Arg8 conjugates of 17-desacetylvinblastineTrp. R= -NH-Arg-
(Arg)6-Arg-CONH2.
The conjugation reaction resulted in two isomers with different retention times, but with the 
same molecular mass. Nuclear Magnetic Resonance Spectroscopy (NMR) data suggest that these 
isomers are epimers at the tryptophan carbon atom (Table 2) (Bánóczi 2010).
Table 2: The synthetized 17-DesacetylvinblastineTrp-oligoarginine conjugates and their retention 
times (Rt) obtained by reverse phase-high performance liquid chromatography (RP-HPLC).
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The antitumor effect of conjugates was studied on sensitive and resistant human leukaemia 
HL-60 cells. Data summarized in Table 3 showed that both 17-desacetylvinblastine and 17-
desacetylvinblastineTrp have more marked activity on sensitive HL-60 cells than the oligoarginine 
conjugates; however, this prominent effect decreased significantly in resistant HL-60 cells, showing 
that they are good substrate for multidrug resistance transporter proteins (such as P-pg, MRP1) 
expressed in this cell line. In contrast, the oligoarginin conjugates showed almost similar effect on 
resistant cell lines. The antiproliferative effect of the conjugates increased with the number of 
arginine (Arg) residues present on the conjugates: Arg8 > Arg6 > Arg4. The octaarginine conjugates 
exhibited essentially similar level of antitumor activity on sensitive and resistant HL-60 cell (Table 
3) indicating that they are promising anticancer agents (Bánóczi 2010).
IC50 [ M]
HL-60 HL-60/MDR1 HL-60/MRP1
17-desacetylvinblastine 0.0043 1.78 0.24
17-desacetylvinblastineTrp 0.49 59.60 3.98
17-desacetylvinblastineTrp-Arg8-1 1.61 2.62 2.94
17-desacetylvinblastineTrp-Arg8-2 1.59 2.94 3.78
17-desacetylvinblastineTrp-Arg6-1 0.97 4.70 9.76
17-desacetylvinblastineTrp-Arg6-2 1.75 6.90 9.76
17-desacetylvinblastineTrp-Arg4-1 5.25 9.52 11.12
17-desacetylvinblastineTrp-Arg4-2 4.97 17.20 14.34
Table 3: Cytostatic activity of vinblastine derivatives on sensitive and resistant HL-60 cells. The 
IC50 values were determined by MTA assay.
3.1.3 Post-translational modifications of tubulin
Tubulin receives diverse post-translational modifications (PTMs) which include acetylation, 
tyrosination, detyrosination, polyglutamylation, polyglycylation, palmitoylation, and 
phosphorylation (Westermann 2003, Verhey 2007, Hammond 2008, Fukushima 2009). The first 
implication of a tubulin PTM was the tyrosination of brain tubulin reported in 1974 (Barra 1974). 
Earlier studies focused on the profiles and physiological relevance of modified tubulin and revealed 
that some PTMs are associated with microtubule age (Fukushima 2009), however, it has been
recently demonstrated that at least some PTMs do not appear to change the intrinsic properties, such 
as stability of microtubules, rather they have been postulated to “mark” subsets of microtubules and 
influence the binding of MAPs, molecular motors and +TIPs (Reed 2006, Hammond 2008).
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3.1.3.1 Microtubule acetylation
Acetylation occurs after microtubule assembly at the Lys40 of -tubulin which is preserved 
in all -tubulin isoforms but not in -tubulin (Fukusima 2009). Considering its function, the 
reversible acetylation was correlated first with increased stability of microtubules (Maruta 1986, 
Piperno 1987, Webster 1989, Hubbert 2002, Matsuyama 2002), as long-lived stable microtubules 
are enriched with tubulin acetylation (Webster 1989). However, the role of -tubulin acetylation in 
microtubule stabilization is not well established and other authors suggest that microtubule 
acetylation does not increase the level of stable microtubules; rather, microtubules must be 
stabilized by other mechanism and then these microtubules accumulate acetylated tubulin (Palazzo 
2003, Haggarty 2003). This modification was proposed to function afterwards as a “road sign” on 
microtubules and control motor-protein based polarized trafficking events. Acetylation level of 
microtubules has already been proved to affect a variety of intracellular trafficking events via its 
influence on the binding and motility of motor-protein from the kinesin and dynein superfamilies 
(Reed 2006, Liao 1998, Ikegami 2006, Bulinski 2006, Dompierre 2007, Verhey 2007, Hammond 
2008). Thus microtubule acetylation via its influence on polarized microtubule-based trafficking 
plays essential role in such elemental processes as cell differentiation, polarization and movement 
(Alberts 2008) and is involved in the etiology of certain neurodegenerative diseases (Dompierre 
2007, Outeiro 2007, Suzuki 2007). 
Two enzymes are responsible for the deacetylation of acetylated tubulin: the ubiquitous 
histone deacetylase 6 (HDAC6) (Hubbert 2002) and the presumably brain specific mammalian 
homolog of silent information regulator 2 / sirtuin type 2 (SIRT2) (North 2003). Both enzymes 
belong to the family of Histon Deacetylases (HDACs) (Marks 2003). The members of HDACs are 
generally localized in the nucleus and regulate chromatin relaxation and gene transcription, as
histone deacetylation favors chromatin condensation and transcriptional quiescence. However, 
recent studies have identi ed an expanded substrate repertoire for HDACs and have shown that the 
function of these molecules is not limited to histones, but there are specific ones in the cytosol 
which are responsible for tubulin deacatylation for example (Valenzuela-Fernandez 2008). 
Considering the expression of SIRT2 and HDAC6 in brain, it was demonstrated that 
HDAC6 is expressed in neurons, while SIRT2 is oligodendrocyte specific (Southwood 2006), 
however, the expression of SIRT2 has been recently demonstrated also in olfactory neurons in vivo 
and in hippocampal neurons in vitro (Harting 2009).
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Regulation of microtubule acetylation level denotes innovative aspects since the inhibition 
of the HDAC6 and SIRT2 is considered as potential target mechanism for drugs to treat different 
human central nervous system (CNS) diseases, including HD (Dompierre 2007) and PD (Outeiro 
2007). HD is a neurodegenerative disorder characterized by cognitive and motor de cits. In HD, the 
microtubule-dependent transport of vesicles containing brain-derived neurotrophic factor (BDNF) is 
reduced, resulting in a reduction of trophic support and subsequent neuronal cell death. HDAC6 
inhibition by Trichostatin A (TSA) increased the amount of acetylated microtubule and 
concomitantly stimulated vesicular transport of BDNF in striatum-derived neuronal cell lines 
(Dompierre 2007) via the enhancement of the recruitment not only of kinesin-1 but also of dynein. It
was also demonstrated that acetylated tubulin levels were reduced in HD patients and that TSA 
rescued the transport defect in neuronal cells carrying a polyglutamine expansion, a model of HD. 
PD is characterized by motor de cits, loss of dopaminergic neurons and accumulation of -
synuclein in the midbrain. SIRT2 inhibition by the use of speci c inhibitors or genetic engineering 
was proved to rescue -synuclein induced neuronal toxicity (Outeiro 2007) and also caused
resistance to axonal degeneration in cerebellar granule neurons of mutant mice displaying low 
Wallerian degeneration (Suzuki 2007). 
In contrast to the tubulin deacetylases, the tubulin acetylating enzyme/s (TATs) has/have
only been recently identi ed. A report has shown that an N-acetyltransferase complex consisting of 
N-acetyltransferase1 (NAT1) and arrest defective 1 (ARD1) mediates tubulin acetylation (Ohkawa 
2008). Furthermore, a six-subunit histone acetyltransferase elongator complex has been identified in 
neuronal cells that might be responsible for tubulin acetylation (Creppe 2009). 
3.2 The oligodendrocytes
Oligodendrocytes represent the myelin forming cells of the CNS. They are characterized by 
an elaborate process network terminating in flat membranous sheets that are rich in myelin-specific 
proteins and lipids, and spirally wrap axons forming a compact insulating layer in vivo (Figure 8). 
The development of the myelin sheath allowed the evolution of the highly complex but compact 
nervous system. Oligodendrocytes provide the same functionality as the insulation on a household 
electrical wire. Myelinated nerve fibers propagate electric impulses rapidly by saltatory conduction, 
where action potentials are regenerated at unmyelinated Nodes of Ranvier, rather than by slow 
linear spreading of signals. Failure to form a tightly wrapped myelin sheath (dysmyelination) or to 
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maintain it (degeneration), results in delayed or disrupted signal transduction most clearly illustrated 
in the CNS by the autoimmune disease MS (Bauer 2009).
                          
         Figure 8: Formation of the myelin sheath around the axons of neurons in the CNS.
Oligodendrocytes develop from small proliferative progenitor cells migrating out of the 
germinal zones in the brain and spinal cord. Postnatally, cells cease to migrate, become postmitotic, 
and morphologically differentiate by synthesizing myelin components and extending cellular 
processes, which ultimately form the multilamellar myelin sheath (Richter-Landsberg 2008). During 
this differentiation process the motile progenitor cells, that are characterized by bipolar morphology,
first became multipolar with several short processes and as time passes both the number and the 
length of these processes are increasing (Figure 9). At the end, mature differentiated 
oligodendrocytes in culture are characterized by numerous long processes branching extensively 
into a complex network and by flat membranous sheaths (Richter-Landsberg 2008). Alterations in 
cell shape are to a large part mediated by the cytoskeleton (Bauer 2009). The cytoskeleton and 
particularly microtubules play role during the extension and stabilization of myelin processes, and 
provide a template for active transport of cytoplasmic constituents, participate in intracellular 
sorting processes and in the translocation of the myelin basic protein (MBP) mRNAs and other,
myelin releated proteins to the forming myelin sheath (Richter-Landsberg 2000).        
  
               Figure 9: Morphological changes during oligodendrocyte (OL) differentiation in culture.
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3.2.1 The cytoskeleton of oligodendrocytes
The oligodendrocyte cytoskeleton is composed of microtubules and actin filaments, while 
they are devoid of intermediate filaments. The cytoskeletal elements serve distinct functions in 
oligodendrocytes. While actin filaments mediate primary process outgrowth and basic stability as a 
consequence of their localization immediately beneath the plasma membrane, microtubules have 
been shown to convey a more mechanical stability to processes. Additionally, both serve as 
transport tracks for cellular organelles, vesicles, proteins, and mRNA granules, which are shuttled 
along the microtubules and actin filaments by motor proteins including kinesins and dyneins (Bauer 
2009).
3.2.1.1 The microtubules in oligodendrocytes
Both indirect immunofluorescence and electron microscopy demonstrated that while 
microtubules in the processes are arranged in filaments parallel to the main axis of the process,
microtubules in the cell body form a meshlike pattern rather than emanating from one distinct 
location (Bauer 2009). Considering microtubule polarity, microtubules in the processes show almost 
complete plus-end orientation to the distal ends (Lunn 1997).
3.2.1.2 Post-translational modification of tubulin in oligodendrocytes
The microtubules of oligodendrocytes were reported to contain tyrosinated -tubulin in the 
cell body as well as in large and small processes, and staining for acetylated -tubulin revealed a 
similar pattern; the only obvious difference between the two appears to be that acetylated -tubulin 
does not extend to the most distal tips of the processes (Song 2001, Bauer 2009).
The acetylation level of microtubules via its influence on the polarized microtubule-based 
transport processes is essential in the formation of oligodendrocyte projections, as the anterogradely 
transported compounds are incorporated into the distal ends of the projections mediating process 
outgrowth and differentiation (Ross 2008, Richter-Landsberg 2008, Bauer 2009). Therefore, the 
modulation of the acetylation level of microtubules is crucial in oligodendrocytes: microtubule 
acetylation promotes polarized trafficking, while deacetylation retards it (Tang 2008).
Tubulin deacetylation in oligodendrocytes is mediated by SIRT2 and its expression 
correlates with significant morphological changes necessary for oligodendrocyte differentiation 
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(Bauer 2009): SIRT2 was shown to decelerate cellular differentiation through deacetylation of -
tubulin, while its knock-down increased -tubulin acetylation and the complexity of cellular 
arborization (Li 2007). 
Thus, oligodendrocyte process extension and arborization, especially during myelination, is 
a morphologically and topologically complex process that requires elaborate spatial and temporal 
fine tunings in order to achieve the final topology of the myelin sheath. SIRT2 deacetylase activity 
may therefore, in conjunction with tubulin acetylases and other mechanisms, provide topological 




Recombinant human TPPP/p25 was expressed in E. coli BL21 (DE3) cells and isolated on 
HIS-Select™ Cartridge (Sigma H8286).
4.2 Tubulin and microtubule preparation
MAP free tubulin was purified from bovine brain by the method of Na and Timasheff (Na
1986) and stored in 10 mM phosphate buffer, pH 7.0, containing 1M sucrose, 0.5 mM MgCl2 and
0.1 mM GTP, at 80 C. Purified tubulin showed no contamination with MAPs on overloaded 
sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS/PAGE). Before use, tubulin was 
dialyzed against 50 mM 2-[N-morpholino]ethanesulfonic acid (MES) buffer, pH 6.8 at 4 C for 3 h                   
and then centrifuged at 100 000 g for 20 min at 4 C. The tubulin in the supernatant was polymerized 
in a polymerization buffer (50 mM MES buffer, containing 2 mM dithioerythritol (DTE), 1 mM 
ethylene glycol-bis( -aminoethyl ether)N, N, N’, N’-tetraacetic acid (EGTA), 5 mM MgCl2, pH 6.7)
by adding 20 M paclitaxel to tubulin, followed by incubation at 37 C for 30 min. After 
centrifugation at 100 000 g at 37 C for 25 min, the microtubules were resusspended in 
polymerization buffer.
4.3 DNA manipulations
The coding sequence of TPPP/p25 was obtained by polymerase chain reaction (PCR) using 
the pEGFP-TPPP/p25 plasmid (Lehotzky 2004) as template and the primers 5 -
AGATACACATATGGCT GACAAGGCTAAGC-3  and 5 -GTGCTCGAGCTTGCCCCCTTGC-
3 . The PCR fragment was digested with XhoI and NdeI and cloned between the appropriate 
restriction sites of the pET21c vector (Novagen), resulting in the pET21c-TPPP/p25 plasmid. For 
the construction of the pDsRed2-p25 plasmid, the same template was amplified using the following 
primers: 5’-AGATACTCGAGGGATGGCTGACAAGGCTAAGC-3’ and 5-ATCGAATTCCT
ACTTGCCCCCTTGCACCTTCTGG-3’. The PCR product was digested with XhoI and EcoRI and 
ligated in the pDsRed-C1 vector (Clontech). For the pTRE2hyg-TPPP/p25 construct, the same 
template was used with the primers: 5’-AGATAGGATCCGGATGGCTGACAAGGCTAAGC-3’
and 5-ATCGCTTAGCTACTTGC CCCCTTGCACCTTCTGG-3’. After digestion with BamHI and 




Three synthetic small interfering RNAs (siRNAs) were purchased from Invitrogen and 
designed to target mouse TPPP/p25. The sequence of siRNA1 was: 5’-CCAAUCAGGAAA
GGGCAAGGGCAAA-3’. The sequence of siRNA3 was: 5’-GCCACGUGAUCGAUGGGAA
GAAUGU-3’ and the sequence of siRNA5 was: 5’-GGACAUUGUCUUCAGCAAGAUCAAA-3’. 
Fluorescently labelled scramble siRNA as negative control was obtained from Santa Cruz 
Biotechnology.  
4.5 Surface plasmon resonance (SPR)
SPR measurements were performed on a BIAcore X instrument (GE Healthcare). A stock 
solution of HDAC6 (0.6 mg/ml) was diluted into 50 mM sodium acetate buffer (pH 4.0) at a final 
concentration of 10 g/ml. 100 l of this solution was then injected at a flow rate of 5 l/min on a 
CM5 sensorchip activated by the amine coupling method according to the manufacturer’s 
instructions. The control flow cells were prepared similarly except that the coupling assay did not 
contain HDAC6. For the measurements of the interaction between HDAC6 and TPPP/p25, 30-60 l 
of TPPP/p25 samples were injected at different concentrations over the HDAC6 covered surface at 
a flow rate of 10 l/min. The binding and dissociation of TPPP/p25 was performed in 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.4) buffer containing 150 mM NaCl 
and 0.005% P 20 detergent (GE Healthcare). After each cycle, the chips were regenerated by 
injecting 50 mM NaOH for 30 s. All experiments were repeated at least three times. The steady-
state binding level of TPPP/p25 to HDAC6 was evaluated by non-linear fitting using the 
BIAEvaluation 4.1 software. 
4.6 HDAC6 and SIRT2 activity assays
HDAC6 and SIRT2 activities were measured using a fluorimetric assay kit (BPS Bioscience, 
San Diego, CA, USA) according to the manufacturer’s protocol. The half maximal (50%) inhibitory 




A total of tubulin was assembled to microtubules at 37 C in the polymerization buffer 
by adding 20 M of paclitaxel. Vinblastine, 17-desacetylvinblastineTrp, 17-desacetylvinblastineTrp-
octaarginine conjugates and KAR-2 in 0.5 and/or 1 M concentrations were incubated with tubulin 
at 37 C for 5 minutes before starting the polymerization. Absorbance was monitored at 350 nm with 
a Cary 100 spectrophotometer (Varian, USA) for 6 minutes. To test the stability of TPPP/p25-
bundled microtubules, TPPP/p25-bundled microtubules were made by preincubating 15 M
microtubule with 3 M TPPP/p25 at 37 C for 15 minutes in 0.1 M piperazine-1,4-bis(2-
ethanesulfonic acid (PIPES) buffer (pH 6.6) containing 1 mM EGTA and 1 mM MgCl2 (PEM 
buffer). Depolymerization of samples was induced with a final Ca2+ concentration of 0.75 mM or by
decreasing the temperature from 37 to 4 C or by adding 5 M vinblastine. Depolymerization of 
microtubules in control samples was carried out in the same manner (15 M microtubule in PEM 
buffer). The reactions were followed for 60 minutes at 350 nm with a Cary 100 spectrophotometer 
(Varian, USA).
4.8 Cell cultures
The HeLa cells (ATCC, CCL-2) were grown in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% fetal calf serum (FCS), 1 mM sodium pyruvate, 100 U/ml 
streptomycin and 100 g/ml penicillin (all reagents from Sigma). The cells were grown on 12 mm 
diameter coverslips for microscopic analysis and on 60 mm dishes for all other experiments. 
The CG-4 cells (a kind gift of Dr Jean-Claude Louis, Amgen, CA, USA) were propagated in 
DMEM-N1 medium containing 30% of the same medium conditioned by the neuroblastoma cell 
line B104 (70/30 media), 100 U/ml streptomycin and 100 g/ml penicillin (all reagents from 
Sigma). To promote the maturation of oligodendrocyte progenitor cells into differentiated 
oligodendrocytes, the CG-4 cells were grown in DMEM-N1 supplemented with 40 ng/ml 
triiodothyronine (Sigma) and 20 ng/ml ciliary neutrophic factor (Sigma) (Louise 1992) for 4 days.
For immunofluorescence microscopy, 2x104 cells were plated onto poly-L-ornithine (PLO)-coated 
glass coverslips; for immunoblotting, the CG-4 cells were plated onto PLO-coated 6-well plates 
(105 cells/well), otherwise they were grown on 60 mm PLO-coated petri dishes.
The doxycycline inducible CHO-K1 Tet-On cell line (provided by Prof. Gyula Hadlaczky, 
Biological Research Center, Szeged, Hungary) was maintained in DMEM supplemented with 10% 
Tet-On approved FCS (Clontech) according to the manufacturer’s description. The transfection with 
pTRE2hyg-TPPP/p25 was carried out with Fugene HD reagent (Roche) according to the 
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manufacturer’s instructions and a TPPP/p25 stable expressing clone (CHO10) was selected after 
sub-cloning. For Western-blot analysis, cells were plated in six-well plates, otherwise were grown 
on 60 mm dishes. 
The Caco-2 (ATCC, HTB-37) cells were grown in DMEM high glucose medium 
supplemented with 10% FCS, 1% 1 M Hepes, 1% 100 U/ml streptomycin and 100 g/ml penicillin 
and 1% MEM NEAA (all from Gibco). For immunofluorescence studies, cells were grown on 12
mm diameter coverslips, otherwise they were grown on 60 mm dishes.
For culturing all cells were grown in a humidified incubator at 37 C with 5% CO2.
4.9 Transfections
Transfections of HeLa cells with the pEGFP-TPPP/p25 (Lehotzky 2004), pDsRed-
TPPP/p25, pGFP-End binding protein 3 (EB3) (kindly provided by Niels Galjart, MGC Department 
of Cell Biology and Genetics, EMC, Rotterdam, The Netherlands) and pEGFP-C1 (Clontech) 
plasmids were carried out using Fugene HD reagent (Roche) according to the manufacturer’s 
instructions. The samples were analyzed 24 hours after transfection by immunocytochemistry. The 
CG-4 cells were transfected for 24 hours with 20 ng siRNAs for immunofluorescence microscopy 
and with 120 ng of siRNAs for immunoblotting using Fugene HD reagent (Roche).  
4.10 Drug treatments
When indicated, HeLa cells were treated with TSA (10 nM or 500 nM, overnight), 
nocodazole (0.4 M, in the last 30 min of the transfection period), VBL (0.1 M, in the last 2 hours 
of the transfection period) or curcumin (500 M, overnight) (all reagents obtained from Sigma). The 
combined TSA/nocodazole treatment was carried out by treating the samples with nocodazole (0.4 
M, 30 min) before the end of the incubation with TSA (500 nM, overnight). For cold 
depolymerization, the cells were incubated at 4 C for 90 min before fixation. For cell motility and 
EB3 measurements, the cells were treated with either TSA (500 nM) or paclitaxel (40 nM) for 4 
hours before monitoring. To monitor antimitotic activity, 17-desacetylvinblastineTrp-octaarginine 
conjugates, vinblastine, 17-desacetylvinblastineTrp and 17-desacetylvinblastineTrp-octaarginine-1 
and -2 were added to the medium of HeLa cells in 0.25-5 M concentration range for 24 h. To 
monitor the antimitotic activity of KAR-2 (Richter), Caco-2 cells were incubated with VBL or 
KAR-2 at gradient concentrations from 13 nM to 1 M for 24 houres.
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4.11 Differential extraction of tubulin species
The differential extraction of tubulin and microtubules from the Hela cells was performed 
using a two-step extraction procedure. In brief, 105 HeLa cells/well were plated in a 6-well tissue 
culture plate and incubated overnight. The cells were treated with the agents 500 nM TSA for 4 h 
and 40 nM paclitaxel or 500 nM VBL for 1 h, and the combined TSA/VBL treatment was carried 
out by adding 500 nM VBL for 1 h before the end of the TSA treatment. At the end of the 
incubation, the cells were washed with prewarmed phosphate-buffered saline (PBS) and the soluble 
tubulin fraction was isolated in situ by using 100 l of microtubule-stabilizing buffer (80 mM Pipes,
(pH 6.8), 1 mM MgCl2, 1 mM EGTA, 0.5% Triton X-100, 10% glycerol and protease inhibitors) 
(all from Sigma) prewarmed at 37 C and by keeping the tissue culture plate at the same temperature. 
Next, the cells were quickly washed with prewarmed microtubule-stabilizing buffer, and the 
fractions of polymerized microtubules were extracted in 100 l of microtubule-destabilizing buffer 
(20 mM tris(hydroxymethyl)methylamine, 150 mM NaCl, 1% Triton X-100, 10 mM CaCl2, and 
protease inhibitors, pH 7.4) (all from Sigma) at room temperature. The extracts were chilled on ice, 
and both fractions were centrifuged to obtain a clarified supernatant for SDS-PAGE analysis.
4.12 Immunoblotting
For the Western-blot analysis of CHO10 cells, cells were plated in the standard medium 
(control) or in the induction medium obtained by adding 50 or 500 nM doxycycline (+Dox) and 
incubated for 7 days. On day 6, the cells were split and cultured with or without doxycycline (-Dox). 
For the Western-blot analysis of CG-4 progenitor cells, cells were plated onto six-well plates,
transfected with siRNAs and incubated for 1 day. Cell lysates from CHO10 and CG-4 cells were 
obtained using 150 l of radioimmune precipitation buffer supplemented with protease inhibitor 
mix (Sigma). After lysis, the samples were centrifuged (10 min, 15 000 g, 4 C) and the supernatants 
were stored at -70 C. Protein concentration was determined by Bradford method (Bradford 1976). 
Samples obtained from CHO10, CG-4 and form HeLa cells after differential extraction of tubulin 
species were further analysed by SDS/PAGE. The SDS/PAGE was then followed by its transfer 
onto a polyvinylidene fluoride (PVDF) membrane using wet transfer equipment (Sigma). The 
membranes were subjected to immunoblotting using a rat polyclonal TPPP/p25 antibody (1: 2500, 
Kovács 2007), monoclonal -tubulin antibody (1:5000, DM1A, Sigma) and monoclonal antibody 
against Lys-40-acetylated- -tubulin (1:5000, 6-11B-1; Sigma). Antibody binding was revealed by 
using anti-rat or anti-mouse IgG coupled with peroxidase, ECL® (enhanced chemiluminescence) 
Western-blot detection reagents (Amersham Biosciences) and Kodak X-Omat AR film or 3-amino-
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9-ethylcarbazole as substrate. The optical density of the immunoreactive bands was measured by 
NIH Image J software.
4.13 Immunocytochemistry
For immunofluorescence microscopy analysis, the HeLa and Caco-2 cells were fixed with 
ice-cold methanol for 10 minutes. After 15 minutes in PBS, the samples were blocked for 30 
minutes in phosphate buffered saline (PBS) containing 0.1% Triton X-100 (TPB) and 5% FCS 
(TPB-FCS). The cells were stained with a monoclonal -tubulin antibody (1:1000, DM1A, Sigma) 
or a monoclonal antibody against Lys-40-acetylated- -tubulin (1:1000, 6-11B-1; Sigma) followed 
by Texas-Red conjugated anti-mouse antibody (1:1000, Invitrogen). The samples were washed for 7 
minutes, three times with TPB after each antibody incubation. 
The CG-4 cells were fixed for 5 minutes using 0.25% glutaraldehyde (EM-grade, Sigma) 
and 4% paraformaldehyde (Sigma). The cells were rinsed in PBS (3 X 5 minutes) and residual 
glutaraldehyde was quenched by 0.1 M NH4Cl. The samples were blocked in TPB-FCS for 30 
minutes and sequentially incubated for 1 hour in the presence of the primary and secondary 
antibodies. The rat polyclonal sera against recombinant TPPP/p25 (Kovács 2007) and the 
monoclonal antibody against Lys-40-acetylated- -tubulin were used as described above. The 
affinity purified secondary antibodies against mouse and rat IgGs conjugated with Texas Red or 
Alexa-488 were obtained from Invitrogen. 
The coverslips were mounted with GelMount (or CrystalMount) and sealed with Clarion (all 
reagents from Biomeda). Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI).
4.14 Microscopy
The pictures of fixed samples were acquired on either Leica DMLS epifluorescent 
microscope (Leica Microsystems, Germany) equipped with cooled CCD camera (Spot, Digital 
Instruments, USA), with a 40X or 100X objective, or on Zeiss LSM710 inverted microscope with 
10X objective. All images were processed using Spot 4.0.2 (Leica) or ZEN software (Zeiss).
For densitometric analysis, the images were collected under constant exposure parameters on 
Leica epifluorescent microscope. The determination of acetylated tubulin or TPPP/p25 levels was 
performed by using the Analyze, Measure option of the NIH Image J software. The whole territory 
of each cell was outlined by the Freehand Line tool and analyzed by taking the sum of the grey 
values of the pixels in the selection (Integrated density, IntDen) and by subtracting the background.  
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The time-lapse recordings were performed on a computer-controlled Leica DM IRB inverted 
microscope equipped with 20X/0.4 N-Plan (for cell motility) or 100X (for EB3-GFP motility). The 
cell cultures were kept at 37 C in a humidified 5% CO2 atmosphere within a CellMovie incubator 
(www.cellmovie.eu) attached to the microscope. The objective 100X/1.2-0.6 W N-Plan was 
equipped with an objective heating ring for temperature control. The fluorescent images were 
acquired every 10 minutes for 3 days to follow the cell motility or every 5 seconds for 2 minutes to 
determine the GFP-EB3 motility. All images and videos were processed using the Image J software 
and data were analyzed using the Microsoft Excel software. For time-lapse experiments, the Particle 
Analysis, Manual Tracking Plug-in of ImageJ was used. For cell motility analysis, the position of 
the cells in each time-lapse frame was determined by taking the center of the nuclei. For the 
measurement of GFP-EB3 motility, the tip of the GFP-EB3 dashes was determined for every frame. 
Only dashes that could be followed for at least three consecutive frames were taken into account. 
4.15 Statistical analysis
The error bars represent the standard error of the mean (s.e.m). Comparisons were performed 
using the Student’s t-test and values were considered to be significant if the calculated P value was 
<0.05 (*). 
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                                                              RESULTS AND DISCUSSION
5.1. Microtubule-related functions of TPPP/p25
Microtubule dynamics and organization are regulated by a wide arsenal of regulatory 
proteins including microtubule stabilizing factors, such as structural MAPs (Conde 2009).
TPPP/p25 was identified as a new MAP that induces microtubule polymerization and bundling 
in vitro, co-localizes specifically with the microtubule network in HeLa and NRK cells and 
bundles microtubules at high expression level (Lehotzky 2004). Here we investigated the effect 
of TPPP/p25 on the dynamics and organization of microtubules in order to reveal its role in 
physiological events.
5.1.1 TPPP/p25-induced microtubule bundling enhances microtubule stability
Our previous experiments revealed that TPPP/p25 bundles microtubules in vitro and in 
HeLa cells (Hlavanda 2002, Lehotzky 2004). As microtubule bundling correlates with enhanced 
microtubule stability (Takemura 1992, Umeyama 1993, Barlow 1994), we examined the
influence of TPPP/p25 on microtubule stability.
In the first set of experiments HeLa cells which do not express TPPP/p25 endogenously,
were transiently transfected with pEGFP-TPPP/p25 and for the visualization of the microtubule 
network immunostaining with -tubulin antibody was performed. Figure 10A shows that the 
organization of the microtubule network in untransfected cells (control cells) appeared as fine 
filaments radiating from the centrosome towards the periphery, whereas a subset of 
microtubules were bundled and displayed distinct organization in the TPPP/p25-expressing 
cells. To investigate the effect of TPPP/p25 on the stability of the microtubule network, samples
were treated with VBL, a specific microtubule destabilizing agent. After the addition of VBL, 
the microtubule network depolymerized completely within the untransfected cells leading to 
uniform distribution of the tubulin signal in the cytosol (Figure 10B). In contrast, in EGFP-
TPPP/p25 expressing cells the TPPP/p25-bundled microtubules located around the perinuclear 
region were preserved (Figure 10B). 
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Figure 10: Stability of TPPP/p25-bundled microtubules. Transiently transfected HeLa cells with 
pEGFP-TPPP/p25 were immunostained for -tubulin (red) without (A) and with (B) VBL treatment in 
the nal 2 hours of the transfection period. Note that in the presence of VBL, in non-transfected cells 
(red only) the microtubule network is completely depolymerized, just like the fine bers in the 
TPPP/p25 expressing cells, however, TPPP/p25-bundled microtubules were preserved. Scale bar: 10 
m.
The stability of TPPP/p25-bundled microtubules was also supported in vitro by 
turbidimetric measurements using purified proteins. Incubation of paclitaxel-polymerized 
microtubules with TPPP/p25 induces the formation of microtubule bundles, as we demonstrated 
earlier by sedimentation experiments as well as by electron microscopy (Hlavanda 2002).
Therefore, in this set of experiments tubulin was first polymerized by the addition of paclitaxel 
and then samples was incubated with or without TPPP/p25. As both microtubule polymerization 
and bundling cause an increase in the turbidity of the samples, therefore, the time course 
decrease in turbidity induced by different destabilizing agents/conditions is indicative for the 
disassembly of both single and bundled microtubules. Depolymerization of the samples was 
induced by three distinct methods: decreasing the temperature from 37 C to 4 C, the addition of 
Ca2+ or VBL. As it is shown in Figure 11 A-C, under these conditions the TPPP/p25-incubated
samples displayed higher resistance against depolymerization as compared to the control 
samples.
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Figure 11: Stability of TPPP/p25-bundled microtubules in vitro. Depolymerization effect of low 
temperature (4 C; A), 0.75 mM Ca2+ (B) or 5 μM VBL (C) on the paclitaxel-polymerized microtubules 
treated ( ) or not treated ( ) with TPPP/p25 followed by turbidimetry.
These results indicate that TPPP/p25 plays role in microtubule organization via its 
microtubule bundling activity and also influences microtubule dynamics as the TPPP/p25-
bundled microtubules perform increased stability both in vitro and at cellular level.
5.1.2 TPPP/p25 expression increases microtubule acetylation
       Long-lived, stable microtubules are enriched with PTMs, such as acetylation of -tubulin 
(Webster 1989), thus we investigated the effect of TPPP/p25 expression on microtubule 
acetylation.
           In the first set of experiment, the acetylation level of microtubules was detected in HeLa 
cells, transiently transfected with pEGFP-TPPP/p25, by immunocytochemistry using 
monoclonal antibody against acetylated tubulin. As it is illustrated in Figure 12, the level of 
acetylated tubulin was rather low in HeLa cells (Figure 12B), however, the expression of 
TPPP/p25 within the cells remarkably elevated its level (Figure 12E).
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          Figure 12: Increased tubulin acetylation in TPPP/p25-expressing HeLa cells. Immunostaining for 
TPPP/p25 (green) and acetylated tubulin (red) in untransfected (A-C), pEGFP-TPPP/p25 transfected (D-
F) HeLa cells. HeLa cells did not express endogenous TPPP/p25 (A). TPPP/p25 was detected only after 
transfection (D). The level of acetylated tubulin was very low in HeLa cells (B). However, it increased 
in TPPP/p25-expressing cells (E). Blue: DAPI. Scale bar: 10 m.
To further explore the influence of TPPP/p25 on tubulin acetylation, the cellular extract 
of the stable TPPP/p25 expressing CHO-K1 Tet-On cell line, denoted as CHO10, was
investigated by Western-blot. As it is shown in Figure 13, the uninduced CHO10 cells (no 
doxycycline) displayed a basal activity of the promoter (leakage) generating low level of 
TPPP/p25 (control). When the cells were incubated with 50 or 500 nM doxycycline, TPPP/p25 
was expressed extensively. This elevation in TPPP/p25 level resulted in the concomitant
enhancement of tubulin acetylation. The extent of TPPP/p25 expression was dependent on the 
doxycycline concentration and the higher TPPP/p25 expression level caused more pronounced 
acetylation of the microtubules. In addition, the subsequent withdrawal of the doxycycline from 
the medium decreased the level of TPPP/p25 and this was coupled with a reduction in tubulin 
acetylation. The total tubulin of each sample was found to be virtually constant and was used to 
normalize the relative changes of TPPP/p25 and tubulin acetylation (Figure 13B).
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Figure 13: Level of TPPP/p25 modulates the level of acetylated tubulin in the doxycycline 
inducible CHO10 cell line. (A) Western-blot analysis of TPPP/p25, -tubulin and acetylated tubulin in 
the CHO10 cell line after doxycycline induction showed that 50 nM or 500 nM doxycycline (Dox 50, 
Dox 500) induced robust increase in TPPP/p25 level with concomitant increase of acetylated tubulin 
level, whereas withdrawal of doxycycline (-Dox 50, -Dox 500) resulted in a drop of both. (B) TPPP/p25 
and acetylated tubulin values were normalized after dividing these values by the corresponding control 
and tubulin values. Error bars represent s.e.m. * Significant difference in the ratio of acetylated tubulin 
and tubulin and in the ratio of TPPP/p25 and tubulin between the Dox 50 and the –Dox 50 samples, 
respectively {according to the Student’s t-test, P<0.05}.
              
These results revealed that there is a strong relationship between the level of TPPP/p25 
and acetylated tubulin and suggests that TPPP/p25 is a modulator of microtubule acetylation 
level. 
5.1.3 Acetylation-related enzymes and TPPP/p25 expression                                    
           To evaluate the contribution of the acetylation-related enzymes to the acetylation level of 
tubulin in relation to TPPP/p25 expression, the level of tubulin acetylation was modulated by 
TSA, an inhibitor of HDAC6 (Haggarty 2003), the enzyme responsible for tubulin 
deacetylation, and curcumin that inhibits the activity of the TATs (Balasubramanyam 2004).
In this set of experiments, the changes in tubulin acetylation level were quantified by 
measuring the fluorescence signals of individual cells after immunocytochemistry for acetylated 
tubulin in HeLa cells expressing EGFP-TPPP/p25 and in control (untransfected) cells. Our 
results, summarized in Table 4, showed that the expression of TPPP/p25 increased acetylated 
tubulin level by 70% when compared to the untransfected cells (control cells = 100%). The TSA 
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treatment (at 10 nM and 500 nM) resulted in higher acetylation levels (256% and 487%, 
respectively) when compared to the control. The addition of 10 nM TSA to the TPPP/p25 
expressing cells increased further the TPPP/p25-derived tubulin acetylation (534%) whereas a
higher concentration of TSA (500 nM) did not (490%). It suggests that, at this inhibitor 
concentration, all Lys-40 residues of the microtubule network became post-translationally 
modified and all the available epitopes were occupied by acetylated tubulin antibodies. Addition 
of curcumin reduced only slightly the acetylation level to 83%. However, this effect is still 
prominent since the effect of curcumin manifested in the presence of both TPPP/p25 and TSA 
as well; curcumin reduced the effects of TPPP/p25 and TSA separately (134% and 242%, 
respectively) and was also effective when TPPP/p25 and TSA were combined together (286%, 
as opposed to 490%).
             
Table 4: The effect of the acetylation-related enzymes and TPPP/p25 expression on the 
acetyaltion level of tubulin. HeLa cells transiently transfected with the pEGFP-TPPP/p25 plasmid were 
treated with 10 and 500 nM TSA and/or 500 M curcumin. After overnight incubation, the cells were 
immunostained for acetylated tubulin. The fluorescence signal of individual cells was quantified to 
obtain the acetylation level and expressed relative to the degree of acetylation observed for control cells 
(100%). ± represent s.e.m. *Significant difference in the level of acetylated tubulin between drug 
treated/transfected cells and control cells (according to the Student’s t-test, P <0.05).
These results suggest that the promoting effect of TPPP/p25 on tubulin acetylation could 
result either from the inhibition of HDAC6 or from the activation of the TAT(s) by TPPP/p25. 
acetylation 
level (%)
control         100 ± 12 
10 nM TSA          256 ± 9*
500 nM TSA          487 ± 16 *
curcumin 83 ± 17 *
500 nM TSA + curcumin 242 ± 16 *
TPPP/p25 170 ± 15 *
TPPP/p25 + 10 nM TSA 534 ± 16 *
TPPP/p25 + 500 nM TSA 490 ± 19 *
TPPP/p25 + curcumin 134 ± 21 *
TPPP/p25 + 500 nM TSA + curcumin 286 ± 25 *
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5.1.4 TPPP/p25 promotes microtubule acetylation by the inhibition of HDAC6
To reveal the mechanism responsible for the TPPP/p25-derived tubulin acetylation we 
performed in vitro binding experiments with TPPP/p25 and HDAC6 as well as functional 
studies to establish the potential inhibitory effect of TPPP/p25 on HDAC6 activity. 
The binding of TPPP/p25 to HDAC6 was demonstrated by surface plasmon resonance 
measurements (SPR). HDAC6 was covalently immobilized on the chip and different 
concentrations of TPPP/p25-containing solutions were injected over the surface. A typical 
sensogram measured at 200 nM TPPP/p25 concentration is shown in Figure 14A with the fitted 
curve used to obtain the steady-state (equilibrium) value of bound TPPP/p25 (RU). The steady-
state values were plotted as a function of TPPP/p25 concentration to evaluate the apparent 
dissociation constant (Kd) of the heteroassociation of HDAC6 with TPPP/p25 (Figure 14B), 
which was found to be 112 ± 20 nM.  
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Figure 14: Interaction of TPPP/p25 with HDAC6. Binding of TPPP/p25 to immobilized HDAC6 
was detected by SPR measurements. (A) A typical sensorgram was recorded after injecting 200 nM of 
TPPP/p25 onto the chip for 3 minutes followed by the loading buffer to initiate the dissociation of 
TPPP/p25 from the immobilized HDAC6 (black). The sensorgram was fitted to determine the steady-
state value (red). (B) Steady-state values of the binding vs. injected TPPP/p25 concentration showed 
hyperbolic saturation with an apparent Kd value = 112 ± 20 nM. Error bars represent s.e.m.                                 
The functional effect of TPPP/p25-HDAC6 interaction on the deacetylase activity of 
HDAC6 was measured using a fluorometric HDAC6 assay based on a two steps reaction using 
acetylated lysine substrate. The substrate first is deacetylated by HDAC6, and then the 
fluorophore is released by a second enzymatic reaction. The addition of TPPP/p25 to the 
HDAC6 assay resulted in a concentration-dependent inhibition, reaching almost full (90%) 
inhibition of HDAC6 activity. The IC50 value evaluated from the dose-response curve was 350 
± 60 nM (Figure 15).  
       
          Figure 15: The inhibitory effect of TPPP/p25 on the deacetylase activity of HDAC6. HDAC6 
activity was determined by using a commercial fluorimetric enzymatic assay. The IC50 value 
determined from the relative inhibitory effect of TPPP/p25 vs. TPPP/p25 concentration plot is 350 ± 60 
nM. Error bars represent s.e.m.
.
These results provide evidence for the direct binding of TPPP/p25 and HDAC6 and also 
revealed that TPPP/p25 inhibits the enzyme activity of HDAC6. Thus TPPP/p25 may regulate
the acetylation level of microtubules at cellular level via the inhibition of the deacetylase.
Nevertheless, the promoting effect of TPPP/p25 on the activity of the TATs can not be excluded 
and requires further investigations.
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5.1.5 Effects of tubulin acetylation on the stability of microtubules
It is still a matter of debate in the literature whether tubulin acetylation per se mediates
microtubule stabilization (Matsuyama 2002, Hubbert 2002, Haggarty 2003, Palazzo 2003, Tran 
2007). Thus we investigated the effect of tubulin acetylation on microtubule stabilization. 
Moreover, we also aimed to determine whether TPPP/p25-derived bundling activity or the 
TPPP/p25-derived tubulin acetylation was responsible for the earlier observed stability of the 
TPPP/p25-bundled microtubules against vinblastine treatment.
          In a first set of experiments, the stability of microtubules was investigated by 
immunofluorescence microscopy in HeLa cells transiently transfected with the pEGFP-
TPPP/p25 in the absence or presence of the anti-microtubular agent, nocodazole or by 
incubating the cells at low temperature, that also promotes microtubule disassembly. As it is 
shown in Figure 16, similarly to that observed after VBL treatment, the addition of nocodazole 
resulted in the complete depolymerization of the microtubules in the control cells; the -tubulin
signal distributed homogeneously in the cytoplasm (Figure 16B). In contrast, the bundled 
microtubules of the TPPP/p25-expressing cells showed resistance to nocodazole, whereas the 
unbundled microtubules became depolymerized (Figure 16B). Similar results were obtained 
when the disassembly of the microtubules was induced by cold treatment. To visualize the 
stability of the post-translationally modified microtubule network, samples were immunostained 
for acetylated tubulin. A representative fluorescent picture demonstrates that -tubulin 
acetylation in HeLa cells was significantly higher in TPPP/p25-expressing cells than in the 
untransfected cells (Figure 16C), and the microtubules of TPPP/p25 transfected cell showed
resistance to either nocodazole (Figure 16D) or cold treatment in case of bundling.  
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           Figure 16: Effects of tubulin acetylation on the stability of microtubules. Transiently transfected 
HeLa cells expressing EGFP-TPPP/p25 (A-D, green) were immunostained for -tubulin (A-B, red) and 
acetylated tubulin (C-D, red) before (A and C) and after (B and D) nocodazole treatment. The 
microtubules of untransfected cells (TPPP/p25 negative cells) were depolymerized after nocodazole 
treatment - the signal of -tubulin and acetylated tubulin was distributed homogeneously in the 
cytoplasm - whereas TPPP/p25-bundled microtubules were preserved in the transfected cells (B and D). 
Blue: DAPI. Scale bar: 10 m.  
           To monitor the effect of increased acetylation on microtubule stability, a similar set of 
experiments was performed, however, the cells were also treated with TSA. Due to the 
inhibition of HDAC6, virtually all the microtubules became acetylated (Figure 17A). The 
microtubule network was similar to that of the untreated cells immunostained for -tubulin 
(Figure 16A). The subsequent addition of TSA and nocodazole resulted in a complete 
depolymerization of the acetylated microtubules in the untransfected cells. In contrast, within 
the TPPP/p25 expressing cells, only the unbundled microtubules became depolymerized,
whereas the bundled microtubules were preserved (Figure 17B). Similar effect was observed 
after cold treatment.
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         Figure 17: Effect of enhanced tubulin acetylation induced by TSA on the stability of microtubules.
HeLa cells were transiently transfected with the pEGFP-TPPP/p25 (green) and treated with TSA (A) or 
with nocodazole before the end of the overnight TSA treatment (B) and immunostained for acetylated 
tubulin (red). Note that 500 nM TSA significantly increased the level of acetylated tubulin (A). 
Remarkably, the subsequent nocodazole treatment caused depolymerization of the microtubule network 
only in non-transfected cells (B, red only), whereas TPPP/p25-bundled microtubule network was 
resistant to depolymerization (B, orange). Scale bar: 10 m.
In another set of experiment, the stability of the microtubule network in HeLa cells was 
assessed in the absence and presence of paclitaxel, TSA, VBL or TSA+VBL, and the partition 
of the soluble and polymerized tubulins was quantified by Western-blot using -tubulin 
antibody (Figure 18). In untreated HeLa cells, the tubulin appeared predominantly in a 
polymerized form. After VBL treatment, the partition of the tubulin between the two fractions
altered, almost all tubulin appeared in the soluble fraction. In the presence of paclitaxel, as 
expected, the polymerized form of tubulin was exclusively detected. As it can be seen in Figure 
18 lane 4, the acetylation of the microtubules produced by TSA treatment virtually did not 
protect microtubules from the depolymerization induced by the subsequent addition of VBL 
after TSA treatment (TSA+VBL) indicating that tubulin acetylation did not increase the stability 
of the microtubules against VBL-induced depolymerization.      
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Figure 18: Distribution of tubulin between soluble and polymerized fractions of HeLa cells 
treated with VBL, TSA, TSA+VBL or paclitaxel. The soluble (sol) and polymerized (pol) tubulins were 
visualized by Western-blot using -tubulin antibody and quantified by densitometry. The distribution of 
tubulin between the soluble (empty bar) and polymerized (black bar) fractions is illustrated by stacked 
bar chart. For each sample, the total amount of tubulin was calculated by summing the values of the 
corresponding soluble and polymerized pools. The relative fractions were calculated by dividing the 
value of each pool by the total amount of tubulin. 
These results, on one hand, show that microtubule acetylation, induced by the inhibition 
of HDAC6 with its inhibitor TSA, is not able to protect microtubules against such 
depolymerization agents like nocodazole or cold exposure, in accordance with others previous
observations in different cell lines, under distinct conditions (Palazzo 2003, Haggarty 2003). On
the other hand, it suggests that TPPP/p25 induces microtubule stabilization via its microtubule 
bundling activity, independently of its concomitant acetylation promoting activity.
Our results thus reinforce that point of view in the literature which suggests that 
microtubules could not be stabilized by acetylation itself, rather other mechanisms could be 
responsible for this, and these stable microtubules then accumulate acetylated tubulins 
(Matsuyama 2002, Palazzo 2003, Tran 2007). As microtubule acetylation affects the binding 
and the motility of motor proteins that travel along the microtubules and therefore plays 
essential role in all polarized trafficking events (Reed 2006, Bulinski 2007, Dompierre 2007, 
Jiang 2008, Tang 2008), such as cell differentiation, polarization and motility (Alberts 2008), 
TPPP/p25, as a modulator of microtubule acetylation, may be involved in all these cellular 
events.
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5.1.6 Effect of TPPP/p25 on the growth velocity of the microtubules
The inhibition of the deacetylase activity of HDAC6 has been proposed to regulate the 
growth velocity of the microtubules in connection to the mechanism of its deacetylase action. It 
was supposed that under normal circumstances, HDAC6 quickly deacetylates -tubulin and 
dissociates from the microtubule plus end, so that its capping activity should be very transient, 
and should not interfere with microtubule dynamics. However, impairment of deacetylase 
activity could lead to more prolonged contact between the HDAC6 molecule and the 
microtubule tip, making the capping activity of HDAC6 more pronounced, resulting in reduced 
microtubule growth velocity influencing microtubule dynamics (Zilberman 2009). As we 
identified TPPP/p25 as a novel inhibitor of HDAC6, we thought to establish the effect of 
TPPP/p25 on the growth velocity of microtubules.
The growth velocity of microtubules was examined in HeLa cells by time-lapse video 
microscopy using the GFP-coupled plus-end-tracking protein EB3, as a powerful marker to 
visualize microtubule dynamic events (Stepanova 2003). As shown in Figure 19A, the ectopic 
GFP-EB3 protein appeared as many moving fluorescent dashes at the tip of the microtubules. 
The growth velocity was calculated by superimposing two successive images taken at 5-second 
intervals and by measuring the velocity of the displacement of the microtubule tips. In this 
experiment, the HeLa cells were transiently co-transfected with the pDsRed-TPPP/p25 
construct, which rendered it possible to also monitor GFP-EB3 in parallel. Treatment of HeLa 
cells with TSA significantly decreased the degree of the tip displacement and hence microtubule 
growth velocity (Figure 19B), in accordance with a previous observation (Zilberman 2009). The 
analysis of the microtubule growth velocities in the TPPP/p25 expressing cells revealed that the 
presence of TPPP/p25 produces a reduction in the growth velocity, similar to that observed after 
TSA treatment (Figure 19B). Therefore, it is likely that the growth of the microtubules is 
affected by the inhibitory effect of TPPP/p25 on HDAC6. 
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Figure 19: TPPP/p25 decreases microtubule growth velocity. (A) Overlap of five successive 
time-lapse images of EB3-GFP taken at 5-second intervals representing the displacement of EB3-GFP as 
moving comet tail in a control HeLa cell. Scale bar: 2 m. (B) The microtubule growth velocity of the 
DsRed2-TPPP/p25 expressing cells and TSA treated cells decreased when compared to control cells. 
The TPPP/p25 decorated or TSA treated microtubules grew about two times slower than the 
microtubules of the control cells. Error bars represent s.e.m. *Significant difference between TSA 
treated or TPPP/p25 expressing cells and control cells {according to the Student’s t-test, P<0.05}.
This observation, on one hand, showed that TPPP/p25 could act as a HDAC6 inhibitor
also at cellular level not just in vitro, on the other hand, it revealed the regulatory role of 
TPPP/p25 on the growth velocity of microtubules. Since the modulation of the growth velocity 
of microtubules influences microtubule dynamics, it suggests that TPPP/p25 plays crucial role 
in the regulation of microtubule dynamics not only by its microtubule bundling activity 
increasing microtubule stability but also by its influence on microtubule growth velocity.
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5.1.7 Effect of TPPP/p25 on cell motility
We also examined the influence of TPPP/p25 on the motility of HeLa cells since it was 
reported that both tubulin acetylation (Hubbert 2002, Tran 2007, Haggarty 2003, Palazzo 2003) 
and microtubule stabilization (Sgadari 2000, Verschueren 1994) influence cell motility.
The changes in cell motility were assayed by measuring velocity of cellular movements 
by time-lapse microscopy on the basis of their displacement between two successive image 
frames taken at 10-minute intervals. The effect of microtubule acetylation on cell motility was 
studied in HeLa cells. Figure 20 shows that TSA-treated cells displayed decreased cell motility 
when compared to untreated cells (Figure 20). To mimic the effect of microtubule stabilization 
on cell motility, cells were treated with paclitaxel that stabilizes the microtubules without 
changing the level of acetylation at the given concentration (40 nM) (Piperno 1987). The 
measurement proved that microtubule stabilization also decreased cell motility (Figure 20). The 
velocity of the EGFP-TPPP/p25 expressing cells was slower and faster when compared to that 
of TSA- and paclitaxel-treated cells, respectively, whereas the expression of EGFP alone 
showed no influence on cell motility (Figure 20).
Figure 20: TPPP/p25 expression decreases cell motility. The effect of TPPP/p25 expression on 
cell motility was monitored by time-lapse video microscopy. The quantification of the velocity showed 
that both TPPP/p25 expressing cells and TSA-treated cells (500 nM) moved slower than control cells. 
The expression of EGFP alone (after transfection with the pEGFP-C1 plasmid) showed no influence on 
the velocity of the cells. The incubation with paclitaxel (40 nM) gave the highest motility retraction. 
Error bars represent s.e.m. *Significant difference between drug treated or transfected and control cells 
{according to the Student’s t-test, P<0.05}. 
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These results indicate that the expression of TPPP/p25 influences microtubule-derived 
cell motility, however, the precise mechanism of its action requires further investigations as 
TPPP/p25 regulates both microtubule acetylation and stability, two distinct processes regulating 
cell motility. In addition, it was also demonstrated that HDAC6 in uences the actin-dependent 
cell motility as well by altering the acetylation status of cortactin, a protein responsible for actin 
polymerization and branching (Zhang 2007). Hyperacetylation of cortactin was proved to 
prevent its translocation to the cell periphery, block its association with F-actin, and impair cell 
motility (Zhang 2007). Thus decreased cell motility in case of TPPP/p25 expression can also be 
connected to the modulation of the acetylation level of cortactin via the inhibition of HDAC6 by
TPPP/p25.
5.1.8 TPPP/p25 in oligodendrocytes
As TPPP/p25 was shown to be predominantly expressed in myelinating oligodendrocytes 
in human brain (Takahashi 1991, 1993), we performed experiments with the CG-4 
oligodendrocyte progenitor permanent cell line to investigate the TPPP/p25 expression and its 
consequences in oligodendrocytes.
The CG-4 cell line is capable of proliferating with the mitogen(s) secreted by the 
neuronal B104 cell line for unrestricted periods of time, while the withdrawal of the mitogen(s) 
induces the differentiation of the CG-4 progenitors into mature oligodendrocytes with high 
arborization of the projections (Louise 1992). During this differentiation process, the CG-4
progenitor cells, which are characterized by bipolar morphology (Figure 21A), first became 
multipolar with several short processes and as time passes both the number and the length of the
processes are increasing. At the end of the differentiation period (4 days), mature differentiated
oligodendrocytes are characterized by numerous long processes branching extensively into a 
complex network (Figure 21B) in accordance with the morphological changes during 
oligodendrocyte differentiation in vivo (Bauer 2009).
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Figure 21: Morphology of oligodendrocyte progenitor cells and mature oligodendrocytes. Cells 
morphology was analysed before and after the differentiation of CG-4 oligodendrocytes by phase 
contrast microscopy. Progenitor CG-4 cells (A) show bipolar morphology. Differentiated CG-4 cells (B) 
show distinct morphology with highly arborized processes. Scale bar: 20 μm.
TPPP/p25 expression was detected in CG-4 progenitor cells and in mature
oligodendrocytes by fluorescent microscopy after the immunostaining of the samples with 
TPPP/p25 specific antibody. Visual analysis of the fluorescence intensity of the CG-4 cells 
revealed that oligodendrocyte progenitor cells exhibited signi cantly lower immunopositivity 
for TPPP/p25 when compared to the differentiated oligodendrocytes with highly ramified 
processes (Figure 22).
Figure 22: Immunostaining of progenitor and differentiated CG-4 cell for TPPP/p25.  
Differentiated oligodendrocytes (asterisk) showed increased TPPP/p25 immunolabelling (green) as 
compared to the progenitor oligodendrocytes. Nuclei were counterstained with DAPI (blue). Scale bar: 
100 m.
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To quantify this observation we measured the fluorescence signal of individual cell 
bodies within the samples. Figure 23 shows that mature oligodendrocytes contain around five-
to ten-fold higher TPPP/p25 level when compared to the oligodendrocyte progenitor cells.
Figure 23: Quantification of TPPP/p25 level in progenitor and differentiated CG-4 cells. The 
quantification of the TPPP/p25 signal in individual cell bodies was carried out by ImageJ software after 
immunostaining for TPPP/p25. Note the increased TPPP/p25 expression level in differentiated cells 
(OLG) vs. progenitor cells (OLP) (*P<0.05, t-test). Error bars represent s.e.m. 
The observation that TPPP/p25 level is strongly upregulated in mature oligodendrocytes
as compared to the progenitor cells suggests that TPPP/p25 performs crucial role in this cell 
type.
5.1.8.1 TPPP/p25 is crucial for the differentiation of oligodendrocytes
In order to verify the essential role of TPPP/p25 in oligodendrocytes, TPPP/p25 
expression was down-regulated in CG-4 cells by RNA interference, using previously validated 
siRNAs against TPPP/p25 transcript (siRNA1, 3 and 5), kindly provided by our co-worker
Pierre Lau from the NIH (USA) (Lehotzky 2010).
In the first set of experiments, CG-4 progenitor cells were transfected with siRNA3 and
oligodendrocyte differentiation was induced. Immunofluorescence analysis at the end of the 
differentiation period revealed that TPPP/p25 down-regulation led to an increase in the number 
of progenitor cells with faint TPPP/p25 labelling (Figure 24A), as compared to the control 
sample transfected with the scramble siRNA (Figure 24B).
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Figure 24: Influence of TPPP/p25 down-regulation on oligodendrocyte differentiation. 
Representative pictures of differentiated CG-4 cell transfected with siRNA3 against TPPP/p25 mRNA 
on the first day of differentiation period (A) show an increase in cell number at the end of the 
differentiation period when compared to the control sample transfected with scramble siRNA in parallel 
(B) as visualized after immunostaining for TPPP/p25 (red). Blue: DAPI. Scale bar: 25 m.
To quantify the changes in cell number, the experiment was repeated with all the three 
previously validated siRNAs (siRNA1, 3 and 5) and the overall number of cells per random 
microscopic elds was counted in the case of each sample. In cases of siRNA 3 and 5, the 
samples were subjected to a second round of transfection two days after the first transfection to 
enhance the effects of the siRNAs. The measurement presented in Figure 25 demonstrates that 
the down-regulation of TPPP/p25 level during oligodendrocyte differentiation resulted in a two-
to three- folds increase in cell number when compared to the control sample transfected with the 
scramble siRNA. The double transfection was able to increase further this tendency up to four-
to five-folds. 
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Figure 25: Quantification of the increase in cell number due to TPPP/p25 down-regulation 
during oligodendrocyte differentiation. CG-4 cells were transfected with each of the three siRNAs 
against TPPP/p25 transcript on the first day of the differentiation period. At the end of the 
differentiation cells were immunostained for TPPP/p25 and the overall number of cells per microscopic 
field was counted. The samples marked as 2x were subjected to a second round of transfection on the 
third day of differentiation. Note the increase in cell number in case of TPPP/p25 down-regulation, as 
compared to the negative control transfected with the scramble siRNA and the highest cell number 
achieved by double transfection with siRNA3 and 5.
These results showed that TPPP/p25 is crucial in oligodendrocytes. The down-regulation 
of the protein inhibited the differentiation of oligodendrocyte progenitors into mature
oligodendrocytes.
Notably, it should be mentioned that the increase in number of undifferentiated 
progenitor cells in the absence of TPPP/p25 may also indicate that TPPP/p25 promotes cell 
differentiation by impeding cell division. Our observation that the over-expression of TPPP/p25 
in HeLa cells increased the number of cells in the phase of cytokinesis (Figure 24) could 
reinforce this hypothesis. In addition, it was also demonstrated by our co-workers that rapidly 
dividing oligodendrogliomas did not express TPPP/p25 (Preusser 2007). However, further 
experiments are needed to prove the role of TPPP/p25 in cell-cycle inhibition.
   
Figure 24: Effect of TPPP/p25 on the progression of the cell cycle. (A) A representative picture 
of a pEGFP-TPPP/p25 transfected HeLa cell in cytokinesis. (B) The ratio of HeLa cells in cytokinesis as
compared to the total counted cell number. TPPP/p25 expressing and control HeLa cells were visualized 
and counted by uorescent and phase contrast microscopy, respectively. For comparison, 200 
transfected and 400 control cells were investigated for the presence of the cleavage furrow.
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5.1.8.2 Potential role of TPPP/p25 in oligodendrocytes 
           The development and the maintenance of the elaborate process network of 
oligodendrocytes require serious functional and structural changes of the microtubule network
(Bauer 2009). Among the functional changes, the acetylation level of microtubules is essential 
(Tang 2008), as this PTM affects polarized microtubule-based trafficking required for the 
formation and the maintenance of the projections (Li 2007, Creppe 2009). As TPPP/p25 was 
proved to be involved in the regulation of microtubule acetylation level in HeLa and CHO cells,
we supposed that TPPP/p25 plays crucial role in oligodendrocytes via its influence on 
microtubule acetylation. 
        In order to prove this hypothesis, we investigated the acetylation level of microtubules in 
parallel with TPPP/p25 expression level in CG-4 progenitors and mature oligodendrocytes. 
Samples were immunostained for acetylated tubulin and TPPP/p25 and visualized by 
fluorescence microscopy. As it is demonstrated in Figure 25, the CG-4 progenitor cells, which 
express low level of endogenous TPPP/p25 (Figure 25A), showed immunopositivity for 
acetylated tubulin (Figure 25B) and its level increased concomitantly with that of TPPP/p25 in 
mature oligodendrocytes (Figure 25D and E).
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Figure 25: Concomitant increase of acetylated tubulin and TPPP/p25 levels during the 
differentiation of CG-4 cells. Immunostaining for TPPP/p25 (green) and acetylated tubulin (red) in 
oligodendrocyte progenitor (A-C) and differentiated (D-E) CG-4 cells. The oligodendrocyte progenitor 
CG-4 cells expressed endogenous TPPP/p25 (A) and the tubulin was acetylated (B). In differentiated 
oligodendrocytes, TPPP/p25 (D) and acetylated tubulin (E) levels were higher when compared to that of 
the progenitor cells. Blue: DAPI. Scale bar: 10 m.
To investigate further the relationship between TPPP/p25 and tubulin acetylation level, 
TPPP/p25 was down-regulated in oligodendrocyte progenitor cells by siRNA1 against 
TPPP/p25 transcript. As it is demonstrated in Figure 26, the down-regulation of TPPP/p25 
(Figure 26C) led to decreased acetylated tubulin level (Figure 26A) when compared to that of 
the untransfected cells (Figure 26D and 26B, respectively). This effect was quantified by 
measuring the fluorescence signals of individual cells after immunostaining of the samples with 
TPPP/p25 and acetylated tubulin antibodies (Figure 26E). Results showed a 40% decrease in 
TPPP/p25 level and around 20% decrease in acetylated tubulin level when compared to the 
sample transfected with a scramble siRNA (100%). This finding was further confirmed by the 
Western-blot analysis of the progenitor cells transfected with siRNA1 (Figure 26F), where 
concomitant reduction of TPPP/p25 and acetylated tubulin levels was detected when compared 
to the scramble siRNA transfected sample. As a control, the level of -tubulin remained 
constant within the samples.
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Figure 26: Concomitant decrease of tubulin acetylation and TPPP/p25 levels due to TPPP/p25 
down-regulation in CG-4 progenitor cells. CG-4 progenitor cells were immunostained for acetylated 
tubulin (A-B, red) and for TPPP/p25 (C-D, green). Down-regulation of TPPP/p25 by siRNA1 resulted in 
a decrease of both TPPP/p25 (D vs. C) and acetylated tubulin levels (B vs. A). Blue: DAPI. Scale bar: 
10 m. (E) Acetylated tubulin and TPPP/p25 levels were quantified by the fluorescence signal of 
individual cells and were expressed relative to the protein levels measured in the control, untransfected 
cells (100%). Error bars represent s.e.m. *Significant difference in the levels of acetylated tubulin and 
TPPP/p25 between control and transfected samples {according to the Student’s t-test, P<0.05}. (F) 
Western-blot analysis of acetylated tubulin and TPPP/p25 levels after transfection of CG-4 progenitor 
cells with siRNA1 (F, lane 1-2, from parallel samples) and with scramble siRNA (lane 3-4, from parallel 
samples). Tubulin was used as a loading control.
These results indicate that there is a strong correlation between TPPP/p25 and acetylated 
tubulin levels in oligodendrocytes.
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5.1.8.3   TPPP/p25 inhibits the deacetylase activity of SIRT2 
While HDAC6 is extensively expressed in HeLa and CHO cells, in oligodendrocytes the 
modulation of tubulin deacetylation may be largely, if not exclusively, down to SIRT2 
(Southwood 2007, Tang 2008). Therefore, we performed measurements to test the effect of 
TPPP/p25 on the activity of SIRT2 with a similar fluorometric assay as in the case of HDAC6. 
The result of the experiment presented in Figure 27 shows that TPPP/p25 is able to inhibit the 
activity of SIRT2 in a concentration dependent manner. The IC50 value evaluated from the 
dose-response curve was 1282 ± 223 nM.
Figure 27: The inhibitory effect of TPPP/p25 on the deacetylase activity of SIRT2. Activity of 
SIRT2 was determined by using a commercial fluorimetric enzymatic assay. The IC50 value determined 
from the relative inhibitory effect of TPPP/p25 vs. TPPP/p25 concentration plot is 1282 ± 223 nM. 
Error bars represent s.e.m.
These results indicate that TPPP/p25 may play crucial role in oligodendrocytes and 
during their differentiation by its regulatory role in microtubule acetylation level via the 
inhibition of SIRT2. However, it should be noted that the extension and the maintenance of the 
projections also depend on the organization and stability of microtubules that provide tracks for 
the active transport of constituents to the myelin sheath (Richter-Lansdberg 2008). Therefore 
TPPP/p25 may also play essential role in oligodendrocyte via those TPPP/p25-derived events 
that influence microtubule organization and stability, such as microtubule bundling, enhanced 
microtubule stability and reduced microtubule growth velocity due to TPPP/p25 expression.
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5.2 Drugs affecting microtubule dynamics and organization
Besides the wide arsenal of regulatory proteins that function within the cells, 
microtubule dynamics and organization can be influenced by chemically diverse groups of 
antimitotic drugs used effectively in cancer treatment nowadays (Jordan 2002). However, it is 
great challenge for the drug researchers to produce new derivatives with less serious side effects 
and better bioavailability than these molecules.
5.2.1 Effect of the KAR-2 on microtubule dynamics and organization
Previous experiments showed that KAR-2, a new vinblastine-derivative, displays
significantly lower cytotoxicity but more favourable anticancer potency than its mother 
bisindole molecule in the in vivo tests (Orosz 1999). Here we investigated the effect of KAR-2
on microtubules dynamics and organization in order to contribute to the characterization of its 
anticancer potency.
The effect of KAR-2 on microtubule organization was tested first in vitro by 
turbidimetric assay as the binding of bisindoles to tubulin was proved to inhibit the paclitaxel-
induced tubulin polymerization. We measured the time course of the tubulin polymerization 
without drug as control curve and with KAR-2 or vinblastine at two–two different drug 
concentrations. Figure 28 shows that KAR-2 displayed concentration-dependent inhibition on 
microtubule polymerization: 0.5 M and 1 M of the drug resulted in 30 and 100% inhibitions, 
respectively. This anti-microtubule effect was virtually indistinguishable from that of its mother 
molecule, vinblastine. 
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Figure 28: Effects of vinblastine and KAR-2 on tubulin polymerization as determined by 
turbidimetric assay. Paclitaxel-induced tubulin polymerization in the presence of 0.5 μM KAR-2 (a), 1 
μM KAR-2 (b), 0.5μM vinblastine (c), 1 μM vinblastine (d) and in the absence of drug (e).
To characterize the effect of KAR-2 at cellular level, we investigated the organization of 
microtubules in human colorectal adenocarcinoma (Caco-2) cells after KAR-2 treatment and 
compared its effect to that of vinblastine. The two drug molecules at various concentrations 
were added to the medium of the cells and after 24 hours incubation cells were investigated by 
fluorescence microscopy after immunocytochemistry for -tubulin. 
As it is demonstrated in Figure 29, the microtubule network of the KAR-2 treated cells 
in interphase can be characterized by three well-defined stages. Microtubules in normal stage 
(Figure 29A) are originated from the microtubule organizing centre and their free ends radiated 
outward toward the cell membrane, forming a network. By the enhancement of drug 
concentration, the microtubule network of the cells tends to consist of short microtubule fibers 
that are positioned in the cytoplasm in a criss-cross fashion: fragmentated stage (Figure 29B). 
Finally, at the highest drug concentration all the microtubules disassembled, the -tubulin 
showed homogeneous cytosolic distribution: depolymerized stage (Figure 29C).
Figure 29: Categories of the interphase microtubules: normal (A), fragmentated (B) and 
depolymerized (C) in Caco-2 cells caused by KAR-2 at different concentrations (13, 130 and 500 nM, 
respectively) as visualized by fluorescent microscopy after -tubulin immunostaining. Blue: DAPI. 
Scale bar: 5 m.
Considering the organization of the spindle microtubules after KAR-2 treatment, the 
most pronounced alterations were observed in metaphase and can be categorized into four 
typical types. In normal metaphase (Figure 30A) high number of kinetochore microtubules 
connects the chromosomes and the centrosomes together forming a symmetric bipolar astral 
array. These microtubules are relatively long, in contrast, the astral microtubules are short and 
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hardly visible. The centrosomes are positioned in perpendicular position to the equatorial plane 
of the chromosomes giving a proper axis for the segregation. This symmetric spindle 
organization became increasingly distorted with the elevation of drug concentration and was 
denoted as aberrant. The orientation of the spindles was either shifted from the equatorial plane 
(asymmetric metaphase, Figure 30B) or originated from more than two poles (multipolar 
metaphase, Figure 30C) leading to unequal chromosome segregation and aberrant mitosis. 
Finally, at the highest drug concentration complete depolymerization of the spindle 
microtubules was observed: unorganized phase (Figure 30D).
Figure 30: Categories of the spindle microtubules: normal (A), asymmetric (B), multipolar (C) 
and unorganized in Caco-2 cells caused by KAR-2 at different concentrations (6, 13, 25 and 500 nM, 
respectively) as visualized by fluorescent microscopy after -tubulin immunostaining. Blue: DAPI. 
Scale bar: 5 m.
The transition from metaphase to anaphase is an important checkpoint in the cell cycle, 
which prevents cells from progressing into anaphase until the spindle is fully assembled and the 
chromosomes are properly poised for separation ensuring the equipartitioning of chromosomes 
to two daughter cells (Jordan 2002). Aberration in the normal spindle and chromosome 
organization (as the consequence of the disruption of rapid dynamics of spindle microtubules in 
the presence of drugs) results in cell cycle block in metaphase to anaphase progression, and 
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mitotically blocked cells eventually die by apoptosis (Jordan 2002). Thus we suppose that KAR-
2 exerts its antimitotic effect at this cell-cycle checkpoint.
For the evaluation of the antimitotic potency of KAR-2, we quantified the relative 
amount (%) of the aberrant metaphases as compared to all mitotic cells and the structure of the 
interphase microtubules was determined according to the categories presented above at each 
drug concentration. The analysis presented in Table 5 showed that 13 nM and 25 nM 
concentrations of KAR-2 were able to induce 98% and 100% aberrant mitosis formation, 
respectively, without significant disturbance of the interphase microtubule network.
VBL KAR-2
Aberrant M (%) Interphase MT Aberrant M (%) Interphase MT
Control 2 normal 2 normal
M 100 depolymerized 100 depolymerized
0.5 M 100 depolymerized 100 depolymerized
250 nM 100 depolymerized 100 fragmentated 
130 nM 100 depolymerized 100 fragmentated 
50 nM 100 depolymerized 100 fragmentated 
25 nM 100 depolymerized 100 normal
13 nM 100 depolymerized 98 normal
Table 5: Evaluation of the effects of KAR-2 and vinblastine at different concentrations on the 
microtubules of Caco-2 cells as quantified by the relative amount (%) of the aberrant metaphases (M) as 
compared to all mitotic cells and the structure of the interphase microtubules (MT) determined 
according to the categories presented above at each drug concentration. The structure of the interphase 
and mitotic microtubules was visualized by immunofluorescence microscopy using monoclonal -
tubulin antibody.
Taking together the results of these sets of experiments we showed that KAR-2 displays 
virtually similar anti-microtubule activity as vinblastine in vitro and showed that there are 
conditions under which KAR-2 selectively destroys only spindle microtubules without affecting 
interphase microtubules. As even in case of cancer, only a small population of eukaryotic cells 
are in mitosis at definitive time points and the majority is in interphase, a drug molecule that 
selectively attacks mitotic cells could display lower cytotoxicity and thus less side effects. We 
suggest that the higher in vivo efficiency of KAR-2 in animal tests, as compared to vinblastine, 
could be explained by its specificity to the mitotic spindles. However, the distinct features of 
KAR-2 from that of its mother molecule, for example the lack of its anti-calmodulin activity as 
well as its better bioavailability that had been demonstrated in our research group, could 
significantly contribute to its efficiency.
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5.2.2 Effect of vinblastine derivative-octaarginine conjugates on microtubule dynamics and 
organization
In order to characterize the effect of 17-desacetylvinblastineTrp-Arg8-1 and its epimer 
17-desacetylvinblastineTrp-Arg8-2 - two new vinblastine-derivatives that performed increased 
efficacy on drug resistant HL-60 cells as compared to their mother molecule - on microtubule 
dynamics and organization we performed similar set of experiments as in the case of KAR-2.
First we measured the effect of the drugs on the paclitaxel-induced polymerization of 
tubulin in vitro by turbidimetric measurement. As it is shown in Figure 31, both vinblastine 
derivative-octaarginine conjugates inhibit microtubule polymerization similarly to vinblastine 
and 17-desacetylvinblastineTrp. The inhibitory effect of 17-desacetylvinblastineTrp-Arg8-2 
conjugate was comparable to that of the vinblastine and 17-desacetylvinblastineTrp, while the 
inhibitory potency of 17-desacetylvinblastineTrp-Arg8-1 conjugate on microtubule assembly 
was less pronounced. 
Figure 31: Effect of vinblastine and its derivatives on tubulin polymerization in vitro by 
turbidimetric assay. Paclitaxel-induced tubulin polymerization in the presence of 1 M vinblastine (b), 
17-desacetylvinblastineTrp (c), 17-desacetylvinblastineTrp-Arg8-1 (d), 17-desacetylvinblastineTrp-Arg8-
2 (e) and in the absence of drug (a).
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To characterize the effect of the vinblastine derivative-octaarginine conjugates at cellular 
level we investigated the organization of the microtubules in HeLa cells, after 24 hour drug 
incubation. 
As it is shown in Figure 32, the microtubule organization was characterized by similar 
categories described in the case of the Caco-2 cells after KAR-2 treatment. The stage of 
interphase microtubules was divided into three categories: normal, fragmentated, depolymerized 
(Figure 32A-C) according to the changes in the microtubule organization. Considering the effect 
of drug treatment on cell division, the most pronounced alterations were also observed in 
metaphase and could be classified into normal (Figure 32D), asymmetric (Figure 32E) and 
multipolar groups (Figure 32F), according to the aberrations in the position and the number of 
the centrosomes, respectively. 
           Figure 32: Categories for interphase (a-c) and mitotic (d-f) microtubule organizations in HeLa 
cells immunostained for -tubulin (green); normal, control (a and d), fragmentated (b) induced by 2.5 
M 17-desacetylvinblastineTrp, depolymerized (c) induced by 2.5 M vinblastine, asymmetric (e) 
induced by 0.25 M and multipolar (f) induced by 2.5 M 17-desacetylvinblastineTrp treatment. Blue: 
DAPI. Scale bar: 5 m.
Data summarized in Table 6 showed that the two vinblastine derivative-octaarginine
conjugates displayed distinct antimitotic potency. 17-desacetylvinblastineTrp-Arg8-1 was able to 
distort mitosis completely (100% aberrant mitosis), without the disruption of the interphase 
microtubules. In contrast, its epimer: 17-desacetylvinblastineTrp-Arg8-2 could induce only a 




























control 2 normal 2 normal 2 normal 2 normal 
0.2 100 depolymerized 47 normal 22 normal nd nd
1 M 100 depolymerized 100 fragmentated 75 normal 45 normal 
2.5 M 100 depolymerized 100 fragmentated 98 fragmentated 75 normal 
5 M 100 depolymerized 100 depolymerized 100 fragmentated 100 normal 
Table 6: Evaluation of the effect of vinblastine and its derivatives on the microtubules of HeLa 
cells at different concentrations. The percentage distribution of the aberrant mitotic spindle among all 
cells in mitosis was quantified by investigating random microscopic fields. Microtubules were
visualized by immunofluorescence microscopy using monoclonal -tubulin antibody. nd: not 
determined.
Results of these sets of experiments, on one hand, showed that the two vinblastine 
derivative-octaarginine conjugates, differing only in conformation, display distinct anti-
microtubule activity and antimitotic potency indicating a marked relationship between the fine 
chemical structure and the biological effect of drug molecules. On the other hand, we revealed 
that there are conditions where 17-desacetylvinblastineTrp-Arg8-1 is highly selective against 
mitotic cells and may thus have less serious side effects in chemotherapy.
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SUMMARY
Microtubules are major structural components in cells. Their dynamics and organization,
which can be affected by several ways including MAPs and the chemically diverse groups of 
anticancer drugs, are central to their biological functions.
In the present work I examined the effect of a new oligodendrocyte specific MAP, 
TPPP/p25, on the dynamics and organization of microtubules in order to identify its potential 
physiological role. Data obtained in vitro and with different cell models expressing TPPP/p25 
either endo- or exogenously revealed that TPPP/p25 influences i) microtubule organization via
its microtubule bundling activity; ii) microtubule dynamics both via its bundling activity 
enhancing microtubule stability and via its regulatory role on microtubule growth velocity due 
to inhibition of the activity of the tubulin deacetylase enzyme: HDAC6 iii) the acetylation level 
of microtubules via its inhibitory role on the activity of both tubulin deacetylase enzymes: 
HDAC6 and SIRT2; iv) cell motility. Finally, the role of TPPP/p25 is essential in 
oligodendrocytes, as the protein is strongly upregulated during oligodendrocyte differentiation 
while its down-regulation by RNAi inhibited the maturation of oligodendrocyte progenitor cells
into mature oligodendrocytes. Therefore, we suggests that the physiological role of TPPP/p25 in 
oligodendrocytes is the regulation of the acetylation level of microtubules, that post-translational 
modification promotes polarized microtubule-based trafficking essential for the maintenance 
and the development of the oligodendrocyte projections, while TPPP/p25-bundled and stabilized
microtubules could serve as tracks for these trafficking events. Finally, the role of TPPP/p25 in 
the regulation of cell motility could have important impact when oligodendrocyte progenitors
migrate to their final destination in the CNS. Any failure within these TPPP/p25-related 
processes could contribute to the development of different neurodegenerative diseases.
By the examination of the effects of two new potential anticancer agents on microtubule 
dynamics and organization in vitro and at cellular level I revealed that KAR-2 and 17-
desacetylvinblastineTrp-Arg8-1, under certain conditions, preferentially eliminate mitotic cells
and this selectivity may indicate their less serious side-effects in case of chemotherapy.




Az eukarióta sejtek egyik f  vázrendszer t alkotó mikrotubulusok átépülésének 
dinamikája és organizációja elengedhetetlen biológiai funkcióinak betöltéséhez. Ezt a dinamikát
és organizációt számos faktor befolyásolja, így pl. különböz  MAP-ek vagy egyes 
rákgyógyászatban használt gyógyszerek.
Doktori munkámban egy új oligodendrocita specifikus MAP fehérje, a TPPP/p25, 
mikrotubulusok dinamikájában és organizációjában betöltött szerepét vizsgáltam; célom
fiziológiás funkcióinak felderítése volt. In vitro és különböz  sejt-modell rendszerekben kapott 
eredményeim azt mutatták, hogy a TPPP/p25 modulálja: i) a mikrotubuláris váz organizációját
mikrotubulus-kötegel  hatása révén; ii) a mikrotubulusok dinamikáját egyrészt mikrotubulus-
kötegel  hatása - mely a mikrotubulusok stabilitását növeli -, másrészt a mikrotubulusok
növekedését szabályozó hatása révén, melyet a tubulin deacetiláz enzim: a HDAC6 gátlása 
révén ér el; iii) a mikrotubulusok acetilációjának szintjét mindkét tubulin deacetilálásáért felel s 
enzim, a HDAC6 és SIRT2 aktivitásának gátlása révén; iv) a sejtmozgást. A TPPP/p25 szerepe 
az oligodendrocitákban alapvet  fontosságú: expressziója jelent sen megn  az oligodendrociták 
differenciációja során, míg szintjének csökkentése RNS interferenciával a differenciációs 
folyamat során annak gátlásához vezet. Mindezek alapján feltételezzük, hogy a TPPP/p25 
fiziológiás funkciója a mikrotubulusok acetilációs szintjének modulálása, mely poszt-
transzlációs módosítás szabályozza a polarizált mikrotubulus alapú transzportot, így jelent s 
szerepet játszik az oligodendrocita nyúlványok növekedésében és fenntartásában, valamint 
mikrotubulus-kötegel és stabilizáló hatása szükséges lehet ezen transzport folyamatokhoz 
elengedhetetlen “útvonalak” kialakításában. A TPPP/p25 sejtmozgásra gyakorolt hatása szerepet 
játszhat az oligodendrociták vándorlása során a központi idegrendszerben. Bármely zavar 
mindezen TPPP/p25-höz kapcsolható folyamatokban hozzájárulhat különböz  neurodegeneratív 
betegségek kialakulásához.
A két új potenciális rákellenes molekula mikrotubulus dinamikát és organizációt 
befolyásoló hatásait vizsgálva kimutattam, hogy adott körülmények között a KAR-2 és a 17-
dezacetilvinblasztinTrp-Arg8-1 szelektíven pusztítja el az osztódó sejteket, ezáltal potenciálisan 
kisebb mellékhatással rendelkezik majd kemoterápiában történ  alkalmazásuk során.
Összegzésképpen, eredményeim megmutatták a TPPP/p25 és a drog molekulák szerepét 
a mikrotubulusok sokrét  funkcióinak modulálásában.
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